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General Introduction 
After birth, calves undergo huge immunological and metabolic changes. Though 
relatively mature when born they must adapt to various morphological and functional 
changes after birth (Blum and Hammon, 2000; Hammon et al., 2012). Because of 
impaired neonatal management like colostrum management, calf losses are highest in 
the first weeks of life, mainly due to respiratory and digestive diseases. In the United 
States 2.3 million calf losses were counted in 2010 (USDA, 2011).  
Oxidative stress is assumed to play a key role in numerous diseases as almost any 
disease is somehow related to an increased formation of reactive oxygen species 
(Halliwell, 1991). In calves, increased levels of markers for oxidative stress were found 
during the first days of life (Stohrer et al., 2003; Alexandrovich and Antonovna, 2009) 
and during sickness (Ahmed and Hassan, 2007; Al-Qudah, 2009). Furthermore, the 
nutrient status highly affects the antioxidant system (Schwerin et al., 2002; Sies et al., 
2005) and often is impaired in newborn calves due to the change from intrauterine 
continuous energy and nutrient supply via placenta to discontinuous oral supply after 
birth. Thus, improvement of the antioxidant status in newborn calves may contribute to 
the development of an own defence against environmental threats, which helps to 
reduce calf losses and to improve health status during the neonatal development.  
Because flavonoids as phenolic compounds are claimed to be strong antioxidants and to 
have countless other health-promoting effects, they are claimed and marketed as health-
promoting substances by the feeding industry. Especially since the ban of antibiotic 
growth promoters in the European Union in 2006, these ʻgreen’ feed additives gained 
enormous popularity all over the world. However, any in vivo biological effect of a 
substance requires its bioavailability (BV). In contrast to several monogastric species, 
where BV of flavonoids is extensively investigated, knowledge on BV of flavonoids in 
neonatal calves is still lacking. Thus, the aim of this study was to investigate the oral 
BV of the flavonol quercetin, one of the most abundant flavonoids in nature, fed either 
as aglycone or as its glycoside rutin in neonatal calves. Studies were carried out on days 
2 and 29 of life to show possible differences in absorption, distribution, and metabolism 
of quercetin during ontogenetic development of newborn calves. Furthermore, oral 
supplementation with quercetin and catechins for a three-wk period provides 
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information of flavonoid effects on metabolic and antioxidative status in neonatal 
calves.  
This thesis is structured in 4 major chapters. At first, chapter 1 shows an overview of 
flavonoids and their BV and introduces major aspects of the antioxidative system and 
metabolic status in neonatal calves. Chapter 2 deals with the relative oral bioavailability 
of quercetin fed as quercetin aglycone or as its glucorhamnoside rutin in neonatal 
calves. Chapter 3 focusses on the effects on the metabolic and antioxidative status in 
neonatal calves during oral supplementation of quercetin aglycone, rutin, and catechins. 
Finally chapter 4 presents a general discussion of the results of chapter 2 and 3 in 
consideration of present knowledge in the literature.  
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1. Literature Overview 
1.1 An introduction in flavonoids 
1.1.1 Chemical structure and natural occurrence 
Flavonoids are polyphenols, which represent aromatic compounds with one or more 
hydroxyl groups directly linked to a benzene ring from the common three-ring nucleus. 
The chemical backbone is based on a C6–C3–C6 carbon framework. Differences on the 
C-ring divide the flavonoids into six main classes: Flavanols, flavones, isoflavones, 
flavanones, flavonols, and anthocyanidins (Figure 1.1; Dangles and Dufour, 2006; 
Manach et al., 2004). Differences between flavonoid classes are predicated by the 
saturation of the heterocyclic C-ring, which means the presence or absence of a double 
bond on position 4, the degree of oxidation, and the position of the B-ring (flavones and 
isoflavones). These variations lead to more than 6,000 different forms of flavonoids 
known today (Harborne and Williams, 2000). Naturally flavonoids mostly occur as 
glycoside, which means the C-ring is attached to a sugar moiety. A flavonoid without a 
sugar moiety is called aglycone. Glycosides yielding glucose instead of other sugar are 
called glucosides. Only in flavanols the presence of glycosides is rare (Hollman and 
Arts, 2000). According to Hollman and Arts (2000) aglycones usually do not appear in 
fresh plants, but after procession. In the class of flavonols there are mainly O-
glycosides. The type of sugar bound is predominantly β-glycosidic and the most 
prevalent sugars next to glucose are arabinose, galactose, and rhamnose.  
The most abundant flavonoid is the flavonol quercetin (Hollman, 2001; Nijveldt et al., 
2001), a pentahydroxyflavon (C15H10O7). Naturally, quercetin is always bound to at 
least one sugar molecule building quercetin-β-glycoside. The type of sugar differs 
between plants (Arts et al., 2004). Williams and Harborne (1994) describe about 179 
different glycosides of quercetin. The main ones are isoquercetin, rutin, and kaempferol 
(Figure 1.2).  
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Delphinidin 
Figure 1.1. Basic structure of the six main flavonoid classes with some representatives for each 
group. In the flavanol structure the numbers and rings are marked. 
Modified from Dangles and Dufour (2006); Manach et al. (2004).  
Quercetin, a yellow crystalline powder with a molar mass of 302.2 g/mol is hardly 
water soluble, but soluble in ethanol or dimethyl sulfoxide. The name quercetin is 
derived from the latin name for oak tree, Quercus, where it was found first. Rutin is a 
glycoside of quercetin bound to rutinose, a disaccharide consisting of rhamnose and 
glucose. It is also a yellow powder, but less hydrophobic than quercetin. Rutinʼs molar 
mass is 610.5 g/mol.  
The most abundant flavonols are catechins, which are colorless and slightly water-
soluble compounds. They are named after catechu, a juice or an extract of Mimosa 
catechu. Due to its isomer structure, catechins occur as trans- (catechins) and cis-
isomers (epicatechins).  
In general, flavonoids are ubiquitous plant components in all kinds of higher plants. 
High amounts of flavonoids can be found especially in onions, broccoli, apples, 
apricots, tomatoes, and kale as well as in black currants, black and green tea, and red 
wine (Hertog et al., 1992; Crozier et al., 1997; Hollman and Arts, 2000). 
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Quercetin 
 
 
  
   Kaempferol 
 
  
Rutin 
 
    Isoquercetin 
  
Figure 1.2. Chemical structure of quercetin, kaempferol, and the quercetin glycosides rutin and 
isoquercetin. 
Modified from Passamonti et al. (2009).  
An overview of the quercetin, kaempferol, catechin, and epicatechin content in selected 
food is given in Table 1.1, based on data from the USDA database for the flavonoid 
content of selected foods, a literature composition based on of 308 different references 
(Bhagwat et al. 2013) retrieved in December 2013. Further databases on flavonoid 
content are available, like the Phenol-Explorer (http://phenol-explorer.eu/) or EuroFIR-
BASIS (http://ebasis.eurofir.org/), and countless single references giving the flavonoid 
content in plants.  
For chemical determination of the distinct flavonoids, an acceptable separation of the 
individual flavonoid molecules must be ensured, for example by high-performance-
liquid-chromatography (HPLC). However, given values for the flavonoid content in 
plants can differ enormously depending on methods of analysis, as there is no 
standardized method for flavonoid analyses. Besides variation of flavonoid content 
among plants, there are many factors that influence the flavonoid content in plants itself, 
like seasonal variation, light and climatic conditions, degree of ripeness as well as food 
preparation and processing (Aherne and O’Brien, 2002). These natural variations in 
plants, type of plant, and measurement should be kept in mind when comparing 
flavonoid content among plants. 
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Table 1.1. Flavonoid content in selected food as is in raw material unless indicated otherwise. 
Source 
Flavonoid content, mg/kg fresh weight or mg/L 
Flavonol Flavanol 
Quercetin Kaempferol Catechin Epicatechin 
Alfalfa, raw seeds 17 0 - - 
Apple 0-115 0-27 0-51 8-192 
Apricot 4-29 0-13 3-73 0-83 
Buckwheat 51-363 - - - 
Blackberry 0-119 0-31 0-3129 0-181 
Broccoli 0-137 1-213 0 0 
Capers 1,493-3,234 2,150-3,083 - - 
Celery 0-35 2 0 0 
Cherry, sweet 1-68 0-7 0-149 4-270 
Chives 9-104 55-125 - - 
Chocolate, dark - - 110-400 520-1,250 
Cranberry 73-250 0-6 0-11 30-57 
Currant, black 23-122 0-23 7 47 
Dock, leaves 862 103 - - 
Elderberry 85-600 2-13 - - 
Grape, black 2-37 0-5 89-108 86-87 
Grape seed - - 60-2,440 230-2,840 
Grape, white/green 1-39 0-3 4-59 1-28 
Kale   0-562 5-905 - - 
Milk, chocolate 1 0 1-2 1-5 
Onion, red 59-1,917 0-45 - - 
Soybeans
2
 0 12 - 374 
Spinach 0-272 0-550 - - 
Tea, black (brewed) 9-48 4-24 4-48 2-87 
Tea, green (brewed) - - 664-6,880 200-216 
wine, red, beverage 0-34 0-13 0-390 0-165 
1
0 = not detectable; - = no data available. 
2
Quercetin and kaempferol content from green soybeans, epicatechin content from mature soybean seeds. 
Modified from Bhagwat et al. (2013).  
Besle et al. (2010) analyzed phenolic compositions of forages fed to dairy cows and 
found the greatest phenolic content in grassland pastures with 35.3 g/kg DM. The 
grassland hay, however, contained 21.6 g/kg DM of phenolic compounds. Ryegrass 
silage versus ryegrass hay contained 16.8 and 14.5 g/kg DM of phenolic compounds. 
The lowest phenolic content was found in corn silage containing 3.7 g/kg DM (Besle et 
al., 2010). Phenolic compounds are also found in trace amounts in bovine milk, wherat 
their concentration is influenced by cow feeding (Besle et al., 2010; Steinshamn et al., 
2008; O’Connell and Fox, 2001).  
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1.1.2 Biological effects of flavonoids in plants  
Flavonoids have multifarious and important functions in plant biochemistry and 
physiology like protecting deoxyribonucleic acid (DNA) from ultraviolet-induced 
damage (Kootstra, 1994). Flavonoids further affect photosynthesis by catalysing 
electron transport processes (Das, 1994). In leaves flavonoid pigments protect the 
underlying photosynthetic cells by absorbing radiation. Most flavonoids accumulate in 
the epidermal cell layer of leaves (Winkel-Shirley, 2002) and in the skin of fruits 
(Manach et al., 2004). The diversity of colors in plants is mainly caused by flavonoids, 
thus flavonoids play a crucial role in attracting pollinators and seed dispersers (Winkel-
Shirley, 2002). Furthermore, flavonoids protect plants against microbial invasion by 
acting as phytoalexins (Harborne and Williams, 2000), increasing tolerance against 
abiotic stressors or defend other herbivory, for example by bitter tasting (Gould and 
Lister, 2006; Harborne and Williams, 2000). The signal transfer between plants and 
microorganisms is also triggered by flavonoids as seen in the stimulation of the 
Rhizobium bacteria for nitrogen fixation (Gould and Lister, 2006). Flavonoids are stored 
in plant vacuoles. Cell death causes flavonoids to disperse into different fluid 
components of the plants like waxes and resins (Das, 1994), which are often considered 
as enriched with flavonoids.  
1.1.3 Biological effects of flavonoids in humans and animals  
The effects of flavonoids in humans and animals are seen ambiguous. On the one hand 
flavonoids are discussed as anti-nutritive factors, whereat on the other hand flavonoids 
are claimed health and performance promoting. Negative aspects of flavonoids are seen 
in tannins, where diminishing BV of proteins and minerals or an inhibition of digestive 
enzymes can occur (Chung et al. 1998). Phytoestrogens are attributed to have adverse 
health effects in infant development (Zung et al. 2001). However, todayʼs research is 
mainly focussed on the positive aspects of flavonoids, especially their antioxidative 
activity and protective capacity against oxidative stress. Flavonoids were found to 
inhibit oxidation of low-density lipoproteins (LDL) in vitro (Harborne and Williams, 
2000). Low-density lipoproteins transport lipophilic substances like cholesterol and 
plasma cholesterol esters. Elevated plasma concentrations of LDL are associated with 
vascular diseases like atherosclerosis (Aviram and Fuhrman, 2003) and related problems 
like coronary heart disease and stroke (Denny and Buttriss, 2005). Therefore, a large 
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body of research deals with the influence of a flavonoid-rich diet on reducing coronary 
heart and vascular diseases (Hertog et al., 1993; Knekt et al., 1996; Rimm et al., 1996; 
Yochum et al., 1999; Hirvonen et al., 2001; Mennen et al., 2004). In spite of all these 
investigations, Loke et al. (2010) postulated the detailed mechanisms of how flavonoids 
may protect against cardiovascular diseases as still unknown. Besides influencing 
cardiovascular diseases, flavonoids are involved in cancer control (Lamartiniere et al., 
1995; Knekt et al., 1997; Hirvonen et al., 2001). Birt et al. (2001) postulated estrogenic 
and antiestrogenic activity, antiproliferation, cell cycle arrest, and apoptosis, as well as 
induction of detoxification enzymes, regulation of host immune function, and other 
mechanisms of flavonoid actions as responsible for tumor growth restriction. 
Furthermore, flavonoids are claimed to be involved in modulation of 
neurodegeneration, especially age-related cognitive and motoric decline, in protection 
against cerebral ischemia/perfusion injuries or other brain abnormalities (Youdim and 
Joseph, 2003). Other neurodegenerative disorders in this context are Alzheimerʼs 
disease, Parkinsonʼs disease, seizures, trauma, and neuroinflammation (Varadarajan et 
al., 2001; Schroeter and Spencer, 2003; Miller et al., 2009). In addition, flavonoid 
treatment may alleviate infection by human immunodeficiency virus, because 
flavonoids are capable to inhibit several critical enzymes involved in life cycle of 
human immunodeficiency virus (Cos et al., 2008).  
Effects of flavonoids and their metabolites on the metabolism in organisms are 
manifold. Especially those on carbohydrate metabolism are well studied and an impact 
on glucose homeostasis was found in several studies. Hanhineva et al. (2010) reviewed 
the impact of dietary polyphenols on the carbohydrate metabolism and summarized the 
inhibition of carbohydrate digestion and glucose absorption in the intestine, the 
stimulation of insulin secretion from pancreatic β-cells, the modulation of glucose 
release from the liver, the activation of insulin receptors and glucose uptake in insulin-
sensitive tissues as well as the modulation of intracellular signalling pathways and gene 
expression as possible mechanisms of how flavonoids influence carbohydrate 
metabolism. More in detail, flavonoids are capable to inhibit α-amylase and α-
glucosidase activity (Tadera et al., 2006), inhibit the sodium-dependent glucose co-
transporter  (SGLT) 1 (Kobayashi et al., 2000) or glucose transporters itself (Johnston et 
al., 2005). In rat insulinoma pancreatic cells polyphenols like quercetin, apigenin, and 
luteolin inhibited cytotoxicity and attenuated the decrease of glucose-stimulated insulin 
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secretion (Kim et al., 2007). However, insulin secretion is affected by a wide range of 
different plant compounds and extracts. Glucose uptake can be stimulated by flavonoids 
in both, insulin-sensitive and non-insulin sensitive tissue, mostly dose-dependent 
(Hanhineva et al., 2010). Glucose transporter (GLUT) 1, widely distributed in fetal 
tissues, and GLUT 4, expressed by muscle, are supposed to mainly trigger flavonoid 
mediated glucose uptake (Hanhineva et al., 2010).  
However, the influence of polyphenols on liver function to maintain glucose 
homeostasis may also play a key role in neonates. Endogenous glucose production as 
important pathway to ensure glucose homeostasis in the neonate (Girard et al., 1992) 
originates from glycogenolysis and gluconeogenesis, both taking place in the liver. An 
improved hepatic glucose and lipid metabolism was indicated in diabetic rats feeding a 
polyphenol-rich diet (Roghani and Baluchnejadmojarad, 2010; Bose et al., 2008; 
Wolfram et al., 2006). In non-diabetic rats, quercetin stimulated glycogenolysis and 
inhibited glycolysis and gluconeogenesis (Gasparin et al., 2003a; b) ex vivo by infusing 
the liver with 50 to 300 µmol/L quercetin. However, these concentrations are not 
achievable with standard diets for in vivo experiments (Gasparin et al., 2003a, b). 
Furthermore, Kobayashi et al. (2010) and Seiva et al. (2012) showed positive effects of 
a flavonoid-rich diet on lipid metabolism in rats fed a high-fat diet as plasma 
concentrations of triglycerides, non-esterified fatty acids (NEFA), insulin, and leptin as 
well as lipogenesis were reduced.   
1.2 Bioavailability of flavonoids  
1.2.1 General aspects of bioavailability with focus on ruminants 
In general, BV can be defined as the rate and extent to which the active ingredient of a 
substance is absorbed in the blood compartment or becomes available at the site of 
action. The European Agency for the Evaluation of Medicinal Products (2000) defines 
BV as the extent and rate to which a substance or its active moiety is delivered from a 
pharmaceutical form and becomes available in circulation. However, the effect of a 
substance is usually determined by its concentration at the place of action.  
All postabsorptive biological effects of given substances depend on their BV. 
Parameters determining BV are liberation, absorption, distribution, metabolism, and 
excretion, abbreviated with their first letters as LADME-system. Liberation, the first 
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step for an effect of a drug or an active compound, means drug release or drug delivery 
and can be seen as a complex process. The drug must disaggregate in smaller particles, 
dissolve in the present fluid, and disperse, which is more difficult for water insoluble 
substances like flavonoids. In the next step, the absorption, the active compound must 
enter the blood or lymph vessels when given orally. Absorption of orally given 
ingredients is determined by solution rate as well as gut and stomach content/filling 
(Frey, 2007). Bioavailability was shown to be influenced by technological (galenical) 
factors of the substance, the form of application, local factors like diarrhea or contact 
with other substances, and first-pass effects. These first-pass effects occur when an 
active compound is metabolized very fast and thus inactivated or transformed before 
entering the systemic circulation, for example in the gut mucosa or liver. After 
absorption into the bloodstream, the active compound is distributed by passive diffusion 
or by convective transport from the blood capillaries into neighboring tissues. The 
metabolism of an active compound means its biotransformation, mainly increasing its 
hydrophilic properties (Pfeiffer et al., 1995). The main organ for biotransformation is 
the liver, but it also takes place in the mucosa cells of the gastrointestinal tract, lung, 
and kidney. Most enzymes involved in this process are located in the endoplasmic 
reticulum (Frey, 2007). Biotransformation is two-phased. Phase-I-reaction is a 
transformation where functional groups are built into non-polar molecules mostly by 
oxidation, reduction or hydrolysis. Absorption to water soluble molecules in phase-II-
reaction enables excretion. The most important ways of excretion or elimination are 
renal, biliary, and intestinal.  
To determine BV, the concentration of an active ingredient is measured over time in 
blood samples collected from the systemic circulation, and as plasma concentration-
time curves are specified only by absorption, distribution, and elimination. To calculate 
BV, area under the curve (AUC), maximal plasma concentration (Cmax), and time until 
the maximal plasma concentration is reached (Tmax) are used as pharmacokinetic 
parameters (see Figure 1.3). 
Bioavailability is either relative or absolute. For determination of the absolute oral BV 
of a substance, the AUC after oral intake is compared to the AUC after intravenous 
injection. In contrast to this, relative oral BV compares two different drugs, containing 
the same active principle after oral application. As time interval of sampling mainly 
determines accuracy, sampling frequency should be as high as possible.  
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Figure 1.3. Illustration of main pharmacokinetic parameters at 2 different plasma concentration-
time curves after a single oral dose of an active compound to an organism. Bold descriptions are for 
curve 1. 
A = absorption; D = distribution; E = elimination; AUC = area under the curve; Cmax = maximal plasma 
concentration; Tmax = time until maximal plasma concentration is reached.  
Modified from Pfeiffer et al. (1995).  
1.2.2 Absorption and distribution of flavonoids in the organism  
Flavonoids can be absorbed in different ways after oral administration from the 
gastrointestinal tract. Quercetin fed as aglycone without attached sugar can be detected 
within 30 minutes after oral administration in plasma of volunteers, whereas quercetin 
fed as rutinoside with attached sugar (rutin) showed delayed peak levels in plasma 
(Hollman et al., 1997b; Olthof et al., 2000; Cermak et al., 2003). Thus, the main place 
of absorption of quercetin monoglycosides is the small intestine. More complex 
quercetin glycosides like rutin are mainly absorbed in the colon or the distal small 
intestine, also colonized with microorganisms (Hollman et al., 1997b; Manach et al., 
1997). Therefore, the sugar moiety and the location of microbial activity in the 
gastrointestinal tract account for different absorption sites (Hollman et al., 1999; Day et 
al., 1998). Some flavonoid aglyca can already be absorbed in the stomach, but not their 
glycosides, as shown in studies in rats administered quercetin (Crespy et al., 2002) or 
daidzein and genistein (Piskula et al., 1999). However, most flavonoid glycosides resist 
acid hydrolysis in the stomach thus reaching the duodenum undegraded.  
To pass the gastrointestinal epithelium is the first crucial step for systemic availability 
in an organism. The enterocytes are polarized cells with numerous membrane proteins 
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that enable the transport of dietary compounds from the lumen into the blood stream via 
channels or active transporters (Figure 1.4). Lipophilic and small nonpolar substances 
can pass the plasma membrane via diffusion following a concentration gradient. As 
flavonoids are polar and thus hydrophilic substances the passive diffusion of flavonoids, 
however, barely occurs in the gastrointestinal tract (Day et al., 2000; Manach et al., 
2004; Crespy et al., 2003). Only for the aglyca a passive absorption is discussed (Day et 
al., 2000; Cermak et al., 2003; Wolffram, 2010). Acidic conditions in the stomach 
inhibit hydrolysis (Day et al., 2000) and pancreatic enzymes are also not able to 
hydrolyze β-glycosidic bounds (Arts et al., 2004). On the contrary Walle et al. (2005) 
found hydrolysis of dietary flavonoids already in the oral cavity by both, bacteria and 
shed epithelial cells, but with a large interindividual variability between volunteers. 
Furthermore, Kahle et al. (2011) found degradation of polyphenols varying after 
incubation with human saliva. Different glucosidases like lactase phlorizin hydrolase 
(LPH) are known to hydrolyze flavonoids (Day et al., 2000; Sesink et al., 2002; Németh 
et al., 2003). Lactase phlorizin hydrolase is an extracellular enzyme from the brush 
border membrane of intestinal mammalian cells and was shown to be important for 
intestinal absorption of quercetin glycosides (Figure 1.4; Sesink et al., 2002). 
Extracellular glucosidases cleave the sugar from the flavonoid glucosides and the 
aglycone can be absorbed. Hydrolysis by lactase phlorizin hydrolase might be reduced 
in rats and sheep due to their higher microbial population in the stomach than in humans 
(Day et al., 2000). In human small intestine and liver an intracellular, cytosolic β-
glucosidase was described that hydrolyze various flavonoid glycosides (Day et al., 
1998). Further enzymes hydrolyzing flavonoids in the gut are glucocerebrosidase (Day 
et al., 1998) and other cytosolic β-glucosidases (McMahon, 1997). More complex 
glycosides, like rhamnosides, are hydrolyzed by enzymes of microorganism in the distal 
small intestine or in the colon (Crespy et al., 1999; Scholz and Williamson, 2007). 
Besides that, active transport systems are prevalently used for flavonoid transport into 
the cell (Figure 1.4). Several studies suggest that quercetin glucosides could be 
absorbed in the small intestine via SGLT 1 (Gee et al., 1998; Walgren et al., 2000a; 
Wolffram et al., 2002). Also GLUT, like GLUT 2 (Chen et al., 2007), are discussed to 
transport quercetin glucosides across the cell membranes. Since the membrane transport 
of xenobiotics, chemical compounds like antibiotics that are neither produced in an 
organism nor are part of the regular diet, is a key factor in medical treatment and 
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flavonoids may interact with the cellular in- and efflux systems like the multidrug-
resistance-associated protein, a plethora of studies with the interaction of flavonoids and 
the membrane transport of drugs or their interactions exists (Cermak and Wolffram, 
2006). Among plasma membrane transporters, the focus is on adenosine triphosphate-
binding cassette transporters (di Pietro et al., 2002; Brand et al., 2006; Morris and 
Zhang, 2006), monocarboxylate transporters, and organic anion and bilirubin 
transporters (Figure 1.4; Passamonti et al., 2009).  
 
 
Figure 1.4. Simplified model of intestinal absorption and metabolism of the flavonol quercetin in 
the organism. 
Solid arrow = enzymatic reactions; dotted or dashed arrow = active or passive transport; SGLT1 = 
sodium-dependent glucose co-transporter 1; LPH = lactase phlorizin hydrolase; CBG = cytosolic β-
glucosidase; UGT = uridine-5´-diphospate glucuronosyl-transferase; MRP = multidrug resistance-
associated protein; SUL = sulfotransferase; GLUT = glucose transporter; ABC = ATP-binding cassette 
transporter; MCT = monocarboxylate transporter; P-Glyc = P-glycoprotein. 
Modified from Murota and Terao (2003); Petri et al. (2003); Cermak and Wolffram (2006).  
However, the exact way of action of these membrane proteins on flavonoid transport in 
vivo is not given yet. Once absorbed into circulation, flavonoids are distributed in the 
body with more than 98 % of quercetin bound to proteins (Gugler et al., 1975; Boulton 
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et al., 1998; Janisch et al., 2004), mainly albumin as the most prevalent protein in 
plasma. Further, quercetin is also bound to glycoproteins and LDL (Boulton et al., 
1998). Depending on their conjugation, the affinity of quercetin to bind on serum 
albumin differs (Janisch et al., 2004) contributing to the huge variation in BV (Dufour 
and Dangles, 2005). However, as it is known that binding of the polyphenol to proteins 
alter their biological activity, the biological effect of this binding needs still to be 
evaluated (Manach et al., 2004).  
The pattern of metabolites in tissues may be different from the one in the blood stream 
due to its cellular uptake or intracellular metabolism (Manach et al., 2004). 
Furthermore, Manach et al. (2004) consider that plasma concentrations do not 
necessarily correlate with the concentration in tissue. Thus, plasma concentration of 
flavonoids may not be an accurate biomarker of exposure to body tissue.  
1.2.3 Metabolism and excretion of flavonoids  
First-pass effect during intestinal absorption is crucial for availability of orally 
administered flavonoids as described in chapter 1.2.1. Hydrolyzation of some 
flavonoids already occurs by passing the enterocytes via the membrane-bound lactase 
phlorizin hydrolase. Other flavonoids are hydrolyzed in the enterocyte by cytosolic β-
glucosidase before entering the systemic circulation (Day et al., 2000, 1998; Sesink et 
al., 2002) and being transported to the liver. Flavonoids reaching the colon are 
hydrolyzed by microorganisms before absorption. In human intestine the presence of 
the bacteria species Eubacterium, Clostridium, and Bacterioides indicated metabolism 
of flavonoids. Various simple aromatic acids are produced in this process and the 
released aglycone is often degraded by colonic microorganisms (Manach et al., 2004). 
These aglycones are further degraded by splitting the heterocyclic ring, thus flavonols 
mainly produce hydroxyphenylacetic acids. Different flavonoid classes lead to different 
acids, like flavones and flavanones are mainly metabolized to hydroxyphenylpropionic 
acids. All breakdown products are further metabolized to derivatives of benzoic acid; 
microbial metabolites are absorbed in the colon and conjugated with glycine, glucuronic 
acid or sulfate (Manach et al., 2004). Due to the different composition of the colonic 
microflora in different species the variations in microbial metabolism of flavonoids are 
enormous.  
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The main site of flavonol metabolism besides the gastrointestinal tract is the liver 
(Hollman and Katan, 1997; Aherne and O’Brien, 2002). Flavonoids are transported to 
the liver via the portal vein. During absorption in the intestine and later in the liver 
flavonoids are conjugated by phase-II-reactions, mainly glucuronidation, methylation, 
and sulfation. Phase-I-reactions like oxidation by enzymes of the cytochrome P450 
system are of minor importance in flavonoid metabolism (Otake et al., 2002). The 
reactions of phase-II mainly are detoxificating processes in the body like metabolism of 
xenobiotics (Manach et al., 2004). When methylated, a methyl group of quercetin is 
transferred, catalyzed by the catechol-O-methyl transferase (Manach et al., 2004), which 
is found in many tissues, with highest activity in liver and kidneys (Piskula and Terao, 
1998). Glucuronidation occurs in the liver, but also to a great extent in the intestine 
(Spencer et al., 1999). This process is catalyzed by the Uridine diphosphate-
glucuronosyltransferase, which is located in the endoplasmatic reticulum. Here, 
glucuronic acid from Uridine diphosphate-glucuronic acid is transferred to the 
polyphenol. Sulfation also mainly occurs in the liver (Piskula and Terao, 1998). The 
transfer of a sulfate moiety from 3´-phosphoadenosine-5´-phosphosulfate to the 
hydroxyl group of polyphenols is catalyzed by sulfotransferases. According to the kind 
of the substance and the ingested dose, the importance of glucuronidation, methylation, 
and sulfation varies (Manach et al., 2004). A higher ingested dose causes a shift from 
sulfation to glucuronidation (Koster et al., 1981). However, the pattern of conjugation is 
further influenced by species, sex or food deprivation (Piskula, 2000).  
Flavonoids formed in the gut mucosa only partially enter circulation and a significant 
amount will be secreted back into the gut lumen (Crespy et al., 1999). This so called 
apical efflux out of the enterocytes is probably triggered by adenosine triphosphate-
binding cassette transporter, like the multidrug resistance associated protein 2 (Walle et 
al., 1999; Walgren et al., 2000b), the breast cancer resistance protein 1 (Sesink et al., 
2005) or the P-glycoprotein (Ofer et al., 2005). 
However, flavonoids often undergo an intensive enterohepatic circulation. Due to their 
biliary excretion back into the duodenum, flavonoids may be further metabolized by 
intestinal microorganisms or reabsorbed from the intestine (Hackett, 1986). This 
recycling may enhance availability of flavonoids in the body (Manach et al., 2004) or 
cause a second plasma peak (Setchell et al., 2001; Manach et al., 2003). According to 
the site of absorption, flavonoids may undergo different metabolic fates, thus the liver 
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might be more important for flavonoids absorbed in the small intestine than for the ones 
absorbed in the colon (Heim et al., 2002).  
Flavonoids and their metabolites usually are excreted by bile or urine. The smaller 
conjugates prefer urinary excretion, whereas the larger and extensively conjugated 
metabolites prefer the biliary one (Manach et al., 2004). Flavonoid glucuronides and 
sulphates are readily excreted with the urine due to their polarity and water solubility 
(Hackett, 1986). However, though various flavonoids are excreted by urine (Aherne and 
OʼBrien, 2002; Scalbert and Williamson, 2000; Manach et al., 2004) this route seems to 
be of minor importance (Hollman et al., 1995). Due to partially long elimination half-
life flavonoids may be accumulated in blood plasma because of repeated absorption 
(Aherne and O’Brien, 2002).  
1.2.4 Factors influencing bioavailability of flavonoids 
Bioavailability of flavonoids may be influenced at all states of the described LADME-
system on both, pre- as well as post-absorptive by species differences and individual 
factors like state of development and nutrition (Heaney, 2001), enzyme activities or 
secretion, other regulatory mechanisms, and interindividual differences (Egert et al., 
2008). Plasma peak concentrations of epigallocatechin gallate increased 3.5-fold when 
catechins were given to fasted compared to non-fasted volunteers (Chow et al., 2005). 
Further, mucosal mass, intestinal transit time, rate of gastric emptying as well as the up- 
and down-regulation of absorption by physiological control because of habituation 
influenced flavonoid BV (Heaney, 2001). Summarized by Scholz and Williamson 
(2007), the most important criterion influencing BV is the attached sugar, followed by 
the food matrix, the added flavonoids, the given dose and the adaption to it, and the 
inhibition of flavonoids by chemical changes after absorption or processing in the 
gastrointestinal tract or due to interactions with other feed components.   
The effects of the food matrix, the physical form in which flavonoids are administered, 
and solubility on BV seem to be more complex. Quercetin is slightly soluble in water, 
but addition of organic solvents such as lipids, emulsifiers (Azuma et al., 2002) or 
propylene glycol (Shimoi et al., 1998) may enhance solubility. The benefit of alcohol on 
BV of flavonoids is discussed ambiguous as some found appreciable improvements 
(Azuma et al., 2002; Dragoni et al., 2006), others not (Donovan et al., 1999; Goldberg 
et al., 2003). However, Azuma et al. (2002) only enhanced BV of flavonoids using 
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alcohol concentrations of more than 30 % in the diet. Overall, composition of the meal 
and the source of flavonoids have the main impact on BV. Quercetin from onions had a 
higher BV than quercetin from apples or pure rutin (Hollman et al., 1997b). Food 
preparation and processing like cooking also affect BV since it can cause a reduction in 
flavonoid content or cause chemical transformation (Manach et al., 2004). Furthermore, 
flavonoid absorption is affected by the fat content in the diet (Lesser et al., 2004).  
Interestingly, interactions of polyphenols with milk proteins partly inhibited positive 
aspects of flavonoids or led to differences in absorption or reduced AUC values of 
flavonoid plasma concentrations (Serafini et al., 2003, Reddy et al., 2005; Egert et al., 
2013). Nevertheless, other studies in humans showed no effect of milk on BV of 
flavonoids (van Het Hof et al., 1998; Hollman et al., 2001).  
1.2.5 Studies on bioavailability of quercetin and catechins 
In cattle, the companion studies of Berger et al. (2012) and Gohlke et al. (2013), where 
quercetin aglycone and rutin were given intraruminal (10 and 50 mg/kg body weight 
(BW); Berger et al., 2012) and intraduodenal (9, 18 or 27 mg/kg BW; Gohlke et al., 
2013) to dairy cows, showed maximal plasma concentrations of flavonols ranging from 
about 20 to 1,000 nmol/L at 30 min to 2 h after administration. Interestingly, rutin was 
much better available than quercetin aglycone after intraruminal (Berger et al., 2012), 
than after intraduodenal administration (Gohlke et al., 2013). Manach et al. (2005) 
reported a range from 0 to 4 µmol/L plasma concentration of total flavonols after intake 
of 50 mg aglycone equivalents in humans, whereas an older study of Gugler et al. 
(1975) found no effect of oral administration on quercetin plasma concentration in 
humans, and therefore suggested oral administration of quercetin as ineffective. 
However, more recent studies revealed detectable plasma concentrations of quercetin 
after oral flavonol administration as shown in Table 1.2. In this overview only studies 
were listed in which pure quercetin substances were administered and plasma 
concentrations were measured. Though lots of BV studies are conducted with food 
containing high contents of flavonoids like apples, wine or onions, interactions with 
other food components or matrix effects cannot be excluded. Therefore, it is more 
reliable using pure substances for comparing BV studies.  
Studies on the BV of catechins with pure substances are rare, as mostly tea extracts 
were used. According to Manach et al. (1999), in rats the catechin metabolites (catechin 
LITERATURE OVERVIEW 
 
 21   
and methylcatechin) reached similar plasma concentrations after oral supplementation 
of catechin than the quercetin metabolites quercetin, isorhamnetin, and tamarixetin after 
quercetin administration in comparable doses. However, metabolites of catechin showed 
a faster decline in plasma concentration than those of quercetin, possibly due to lesser 
binding to plasma albumin or higher urinary excretion (Manach et al., 1999). Hollman 
et al. (1997a), too, postulated a good absorption of catechin and its microbial 
degradation products after oral administration of radioactively labelled (+)-catechin to 
rodents, monkeys, and humans in different studies. Nevertheless, BV of catechins 
widely depends on species, on the administered compound, and on the chemically 
structure of the distinct catechin isomers, such as epicatechin, epigallocatechin, and 
epigallocatechin gallate. In rats fed 200 mg/kg BW of a green tea extract (GTE), Chen 
et al. (1997) found a systemic availability of 31.2 % for epicatechin and of 14 % for 
epigallocatechin, but only of 0.1 % for epigallocatechin gallate, whereas in dogs after 
oral and intravenous administration of 25 mg/kg BW of epigallocatechin gallate 
absolute BV was about 20 % (Swezey et al., 2003). However, systemic available 
epicatechin, epigallocatechin, and epigallocatechin gallate was very low after oral 
administration of 20 mg/kg BW of green tea to humans (Lee et al., 2002) or after oral 
administration of 500 mg/kg BW and intravenous administration of 50 mg/kg BW 
catechin fractions containing 5 % epicatechin, 13 % epicatechin gallate, and 50 % 
epigallocatechin gallate to rats (Zhu et al., 2000). The consumption of a green tea 
beverage by humans resulted in maximal plasma concentrations of total catechins of 
461.8 ± 27.4 nmol/L at 90 min after drinking (Egert et al., 2013). Major catechins in this 
study detected in plasma samples after consumption of various test drinks were 
epigallocatechin gallate (179.9 nmol/L), epicatechin gallate (147.3 nmol/L), 
epigallocatechin (86.5 nmol/L), epicatechin (48.2 nmol/L), and small amounts of 
catechin and gallocatechin (Egert et al., 2013).  
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1.3 Metabolic and health status in neonatal calves  
1.3.1 Metabolic status in calves at birth and postnatal changes 
Although calves are precocial animals and thus relatively mature when born, they still 
must adapt to various morphological and functional changes after birth (Blum and 
Hammon, 2000). During gestation, energy supply is continuously via placenta with 
glucose as main energy substrate. With birth this changes to a discontinuously oral 
supply by colostrum and milk intake with lactose and fat as main energy source 
(Hammon et al., 2013). Prenatal, glucocorticoids and catecholamines as well as thyroid 
hormones in the fetal blood lead to an increased gluconeogenic activity and hepatic 
glycogen storage ensuring coverage of the energy demand of the newborn calf 
(Hammon et al., 2012). However, calves are often hypoglycemic after birth, as they 
need to adapt to the usage of other fuels than glucose, taken up with liquid feeding. 
Thus, endogenous glucose production is an important pathway to ensure glucose 
homeostasis in the calf and increases with maturation (Steinhoff-Wagner et al., 2011). 
Important regulators for endogenous glucose production are hormones like insulin, 
glucagon, catecholamines, growth hormone, and glucocorticoids. The peptide hormone 
insulin is built in the pancreatic β-cells. Plasma concentrations are reduced at birth and 
increase after first feed intake indicating that especially glucose intake stimulates insulin 
secretion (Hadorn et al., 1997; Hammon and Blum 1998; Rauprich et al., 2000). The 
peptide hormone glucagon is built in the pancreatic α-cells and acts as antagonist to 
insulin. Plasma glucagon concentrations also increase after first feed intake in calves 
(Hammon et al., 2012). Endogenous glucose production is in addition stimulated by 
catecholamines, glucocorticoids, and probably growth hormone (GH). Around birth, all 
these hormones showed elevated plasma concentrations in calves and catecholamines 
and glucocorticoids are known for their promoting effects on metabolic maturation in 
the neonate (Hammon et al., 2012, 2013). Plasma concentrations of cortisol are high at 
birth and decrease thereafter (Hadorn et al., 1997; Hammon et al., 2012; Schiessler et 
al., 2002). In addition, cortisol, next to other regulators, is a major player for initiating 
birth (Liggins, 1994). Furthermore, thyroid hormones play an important role for 
endogenous glucose production during late gestation and after birth (Fowden et al., 
2001). Plasma concentrations of thyroid hormones are high at birth and decrease 
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thereafter in mature calves, but not in preterm born calves (Steinhoff-Wagner et al., 
2011). 
In neonatal calves colostrum feeding affects the GH – insulin-like growth factor (IGF) 
system, which most likely is a response to energy supply and improved glucose status in 
calves after colostrum feeding (Hammon et al., 2012). Amount, time point, and 
frequency of feeding influence plasma IGF-1 concentrations (Hadorn et al., 1997; 
Nussbaum et al., 2002), which are lower during the first wk of life in restricted (Hadorn 
et al., 1997) or formula fed calves (Rauprich et al., 2000) indicating the huge 
importance of early and sufficient colostrum feeding to newborn calves for their 
development and maturation.  
1.3.2 Health status in calves and development of the immune system 
Immune defence of newborn calves depends on uptake of immunoglobulins (Ig) with 
colostrum as there is no placental transfer of Ig and endogenous production of Ig is 
negligible (Chase et al., 2008). The ingestion of sufficient colostrum is thus essential for 
immunological protection during the first 2 to 4 weeks of life until calves develop an 
adequate own active immune system (Chase et al., 2008; Figure 1.5). With colostrum Ig 
are transferred from the cow to the newborn calf and activate and regulate the innate 
immune response (Chase et al., 2008).  
 
Figure 1.5. Illustration of the development of immunity and immune response of calves.  
Modified from Chase et al. (2008). 
Apart from nutrients and Ig colostrum contains minerals, vitamins, and also non-
nutrient components like growth factors, cytokines, hormones, and further bioactive 
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substances (Blum, 2006). Most of these non-nutrient factors and bioactive compounds 
are derived from blood of dams, but some are produced in the mammary gland (Blum, 
2006). The average Ig concentrations in bovine colostrum varies greatly, depending 
mainly on breed, age of dam, nutrition in the preparturient period, season or amount of 
produced colostrum (Godden, 2008). As colostrogenesis ends abruptly at parturition the 
greatest concentration of the beneficial compounds is in first colostrum and in further 
milkings concentrations are decreasing because of dilution effects (Godden, 2008). The 
small intestine as the site of digestion and absorption of Ig, mainly IgG, is permeable for 
up to 12 to 48 h after birth (Stott et al., 1979; Baintner, 2007). Feeding the calf leads to 
a faster closure of the gut permeability for great Ig, independent from the amount fed 
(Stott et al., 1979). Small intestinal epithelium includes vacuoles that allow intracellular 
digestion at birth, but soon after colostrum ingestion vacuoles disappear (Blum, 2005). 
Therefore, colostrum influences the gastrointestinal tract as seen among others in 
changes in microbial population, epithelial cell proliferation, protein synthesis, and 
digestion (Blum, 2006). Furthermore, colostrum also exerts long-lasting systemic 
effects on metabolism and endocrine traits by effecting systemic growth, activity, and 
behavior (Blum, 2006).  
Endogenous Ig production and thus active immunity in calves is delayed (Chase, 2008). 
With passive immunity decreasing and active immunity still being insufficient 
susceptibility to diseases is highest in the first wk of life (Figure 1.5), and notable calf 
losses occur with pneumonia and diarrhea being the main reasons for it (USDA, 2011). 
Pneumonia in pre-weaned calves is a multi-factorial disease caused by a number of 
viruses and some calf- and environmental related risk factors (Lorenz et al., 2011). 
Diarrhea is one of the most serious problems in calf rearing worldwide often leading to 
other diseases like pneumonia in enfeebled calves. Furthermore, those calves show 
reduced growth. So calves suffering from diseases in newborn age may show long-
lasting impaired performance.  
1.3.3 Oxidative stress and antioxidative capacity in neonatal calves 
Oxygen is essential for all aerobic living organisms. It is part of several chemical 
compounds like hydrogen peroxide, hypochlorus acid, peroxinitrite, singlet oxygen, and 
ozone. Importantly, oxygen has the potential to destroy cell integrity when building up 
reactive oxygen species (ROS). These ROS can be divided in free radicals and non-
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radicals. In general, a free radical is an atom or molecule with one or more unpaired 
electrons (Halliwell, 1991), marked by the radical dot (·). The most reactive ones are 
hydroxyl radical, superoxide anion, nitric oxide, and peroxyl radical. All these ROS are 
naturally produced in the body during energy production and unspecific immune 
defense, mainly to neutralize bacteria and viruses, and thus protecting the body against 
pathogens. External influences like ionizing radiation, toxins, drugs, and chemicals or 
environmental pollutants can considerably increase the generation of ROS (Sies, 1991) 
resulting in cell toxic conditions.  
The organism has a pool of reducing systems to neutralize these free radicals, called 
antioxidants. These are substances that, when present at low concentrations compared 
with those of an oxidizable substrate, significantly delay or prevent oxidation of that 
substrate (Halliwell, 1991). Antioxidants are divided into enzymatic antioxidants, like 
superoxide-dismutase, catalase or glutathion-peroxidase, and non-enzymatic 
antioxidants, including albumin, carotenoids, bilirubin, uric acid, glutathion, vitamins 
A, C, and E as well as flavonoids. Every aerobe living system is aligned to have a 
balance between these oxidants and antioxidants, but due to inadequate antioxidant 
defense or external influences, an imbalance between the generation of prooxidants and 
the activity of the antioxidant defenses in favor for the prooxidants can occur and is 
called oxidative stress (Sies, 1985, 1991). Oxidative stress is related to numerous 
diseases, the so called free radical diseases. According to Halliwell (1991) for most 
human diseases oxidative stress might be secondary to the primary disease process. 
Next to maturation of the organism (Robles et al., 2001; Saugstad, 2005; Mutinati et al., 
2014) nutrient status and nutrition in general plays a major role in the antioxidant 
system (Schwerin et al., 2002; Sies et al., 2005). However, neonates have a greater 
susceptibility to oxidative stress than adults or juvenile subjects (Saugstad, 2005; 
Mutinati et al., 2014). Main reason therefor is the change from the hypoxic intrauterine 
environment to extrauterine conditions after birth, and the start of regular breathing 
(Robles et al., 2001; Albera and Kankofer, 2011). Especially premature neonates are 
prone to oxidative stress (Robles et al., 2001).  
There are several approaches to measure antioxidative capacity, oxidative stress or free 
radicals. Alam et al. (2013) reviewed 29 different in vivo and in vitro methods for 
evaluating antioxidant activity and oxidative stress. In general, common methods range 
from quantification of (free) radicals, quantification of markers for oxidative stress, like 
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DNA damage or lipid peroxidation, up to the quantification of markers for the 
antioxidant system, like enzymes. Figure 1.6 gives an overview of the most common 
methods for evaluation of oxidative stress and antioxidant capacity. In general, the 
antioxidative status should not only be evaluated by a single test model since there is no 
absolute method (Alam et al., 2013).  
 
 
Figure 1.6. Simplified classification of methods used for determining oxidative stress and 
antioxidant capacity. 
TBARS = thiobarbituric acid reactive substances; F2-Iso = F2-isoprostanes; TEAC = trolox equivalent 
antioxidative capacity; FRAP = ferric reducing ability of plasma.  
Modified from Kohen and Nyska (2002).  
There are plenty of studies describing the antioxidative status or oxidative stress in 
calves, but only a few studies can be compared directly due to different methods of 
analyzing and experimental set-up. Main studies in calves deal with selected parameters 
of oxidative stress or the antioxidant capacity. Stohrer et al. (2003) investigated the 
antioxidant status of cows and calves via trolox equivalent antioxidative capacity 
(TEAC) and found impairment during the first wk of life and thus assumed that 
ischemia/reperfusion injury during birth may affect antioxidative status of neonatal 
calves. Alexandrovich and Antonovna (2009) confirmed an elevated level of oxidative 
stress during the first d of life up to d 45 of age due to an increased level of 
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thiobarbituric acid active products and glutathione when calves were less than 15 d old, 
and reduced values when calves were 50 to 60 d old. The authors assume that the 
transition period in feeding of calves was the reason for that. Also transportation of 
calves leads to an increase of markers for oxidative stress: Wernicki et al. (2006) found 
significantly elevated thiobarbituric acid reactive substances (TBARS) plasma 
concentration in calves that were transported for 2 h. The season did not significantly 
change TBARS levels in calves, but glutathione peroxidase and superoxide dismutase 
were higher in calves born in summer than in calves born in fall (Chigerwe et al. 2013). 
However, in this study no correlation between TBARS and the age of calves was found, 
but there was an obvious correlation between increased oxidative stress or a reduced 
antioxidative capacity and health status of calves. These findings confirmed a study by 
Ahmed and Hassan (2007), who investigated several parameters of calves infected with 
Eimeria species. Malondialdehyde and nitric oxide as markers for oxidative stress were 
elevated in infected calves. Catalase, superoxide-dismutase, ascorbic acid, glutathione, 
and the total antioxidant capacity were significantly reduced in infected calves 
compared to control calves. Bronchopneumonia as a major calf disease similarly 
showed elevated markers of oxidative stress in calves (Al-Qudah, 2009). Also the way 
of delivery seems to influence the antioxidative status since higher malondialdehyde 
and glutathione concentrations in blood showed an exposure to higher oxidative stress 
in calves delivered by caesarian section (Erisir et al., 2013). Retskii et al. (2010) 
‘corrected’ the antioxidant status of newborn calves to form higher colostral immunity 
due to treatment with glucose, ascorbic acid solution, and unithiol and thus reduced the 
incidence and severity of neonatal diseases.  
1.3.4 Effects of flavonoid administration on development and health status in 
neonatal calves 
Countless flavonoid-rich feed additives are marketed claiming improvements in animal 
health and productivity in cattle nutrition. These additives are used in calvesʼ milk 
replacer and in feed for heifers, lactating cows, and fattening cattle 
(http://sanogold.eu/news/2008/flavonoide.php; http://www.pulte.de/Antioxidantien_ 
Botanische_Wirkstoffe&lang=en; http://www.schaumann.de/cps/rde/SID-18 120AAB 
B3-717B45/schaumann-de/hs.xsl/4736.html; http://www.provimi.com.gr/media/grape_ 
pp_concentrate_-_eng.pdf; http://www. gainfeeds.com/ruminant/ goldgrain-calf-nut). 
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In general, lots of feed additives are supposed to reduce or replace antibiotics, thus 
terms like phytobiotics, phototherapeutic or nutraceutical are commonly used. Since 
flavonoids are present in all kinds of higher plants, young ruminants may have 
evolutionary depended on flavonoids (Yaghoubi et al., 2008). However, results of 
studies on feeding flavonoids to young calves are ambiguous. As mentioned, the 
metabolism of calves mainly is influenced by nutrition; hence Yaghoubi et al. (2008) 
postulated an improved growth of calves by feeding flavonoids extracted from propolis. 
Enhancing growth in ruminants by flavonoid feeding is discussed due to possible effects 
on microbial population in the rumen (Aerts et al., 1999; Greathead, 2003) and 
especially in the developing reticulorumen (Yaghoubi et al., 2008; Costa Jr. et al., 
2012). According to Aerts et al. (1999) the degradation of dietary protein to ammonia 
by microorganisms in the rumen of sheep is slowed down by proanthocyanidins, which 
are polymere forms of catechins, and thus increasing the absorption of amino acids in 
the small intestine. Durmic and Blache (2012) also reviewed beneficial effects of 
secondary plant compounds on rumen fermentation, focused on the protection of dietary 
proteins combined with a reduced microbial proteolysis and release into the duodenum. 
However, mainly tannins are building complexes with proteins (Aerts et al., 1999). In 
general, secondary plant metabolites may exert prebiotic effects due to stimulation of 
certain bacteria in the rumen (Greathead, 2003) and affect the immune system as 
hypothesized by Yaghoubi et al. (2008) though the authors found an ambiguous blood 
IgG concentrations after feeding flavonoids to calves. Metwally et al. (2013) reported a 
numeric increase in blood IgM concentrations after feeding propolis extract to buffalo 
calves, considering a non-specific immunostimulating effect. Also Oliveira et al. (2010) 
postulated an improved immune response of calves when feeding a flavonoid-rich 
pomegranate extract due to an enhanced total IgG response after ovalbumin vaccination 
and increased synthesis of interferon-γ and interleukin-4. On the other hand, neutrophil 
phagocytic and killing activities of neutrophils against Escherichia coli did not differ 
when feeding pomegranate extract to young calves (Oliveira et al., 2010). Besides that, 
some flavonoids have hormone-like structures and activities and therefore are called 
phyto-oestrogens (Greathead, 2003) probably exerting anabolic effects in calves. Such 
effects were seen in other species like mice (Sokolova et al., 1978). Furthermore, it is 
noteworthy that quercetin is a major component of several plants used as antidiarrheal 
remedies (Middleton et al., 2000). Di Carlo et al. (1994) showed quercetin feeding 
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ameliorating diarrhea in mice by 92 % in a dose-related manner as did Gálvez et al. 
(1995) in quercitrin (3-rhamnosylquercetin)-treated rats, and Nielsen (2008) in piglets. 
Rao et al. (1997) pointed out a possible antidiarrheal effect of the flavonoid ternatin. 
However, propolis or pomegranate extract feeding did not ameliorate diarrhea in calves 
(Yaghoubi et al., 2008; Oliveira et al., 2010), but feeding a GTE decreased frequency 
and degree of non-pathogenic diarrhea remarkably (Ishihara et al., 2001).  
1.4 Conclusive remarks and need for further research 
Green feed additives like flavonoids have a considerably role in human and animal 
nutrition. Numerous feed supplements containing flavonoids are marketed in the dairy 
industry to improve health, growth, and thus productivity.  
These antioxidative, anti-inflammatory and antimicrobial secondary plant metabolites 
may especially be used in the neonatal period when calves are just developing their 
immune system. However, little is known about the systemic BV of flavonoids and their 
effects in vivo, especially in calves. Thus, the aim of this study is to investigate the BV 
of the most abundant flavonoids quercetin and catechin in newborn calves and to 
examine their effects on selected aspects of the antioxidative status and metabolism. 
Therefore, dairy calves were fed quercetin as aglycone, its glucorhamnoside rutin, and 
catechins for the first 3 wk of life. Parameters of the antioxidative status, oxidative 
stress, and metabolism were determined and studies on BV of quercetin aglycone and 
rutin were performed on d 2 and 29 of life, representing a different ontogenetic status in 
calves.  
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2. Bioavailability of the flavonol quercetin in neonatal calves 
after oral administration of quercetin aglycone or rutin 
Abstract 
Polyphenols, such as flavonoids, are secondary plant metabolites with potentially 
health-promoting properties. In newborn calves flavonoids may improve health status, 
but little is known about the systemically availability of flavonoids in calves to exert 
biological effects. The aim of this study was to investigate the oral bioavailability of the 
flavonol quercetin, applied either as quercetin aglycone (QA) or as its glucorhamnoside 
rutin (RU), in newborn dairy calves. Twenty-one male newborn German Holstein calves 
were fed equal amounts of colostrum and milk replacer according to body weight. On d 
2 and 29 of life, 9 mg of quercetin equivalents/kg of body weight, either fed as QA or as 
RU, or no quercetin (control group) were fed together with the morning meal. Blood 
samples were taken before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24, and 48 h after feed 
intake. Quercetin and quercetin metabolites with an intact flavonol structure 
(isorhamnetin, tamarixetin, and kaempferol) were analyzed in blood plasma after 
treatment with glucuronidase/sulfatase by HPLC with fluorescence detection. Maximum 
individual plasma concentration was depicted from the concentration-time-curve on d 2 
and 29, respectively. Additional blood samples were taken to measure basal plasma 
concentrations of total protein, albumin, urea, and lactate as well as pre- and 
postprandial plasma concentrations of glucose, non-esterified fatty acids, insulin, and 
cortisol. Plasma concentrations of quercetin and its metabolites were significantly 
higher on d 2 than on d 29 of life, and administration of QA resulted in higher plasma 
concentrations of quercetin and its metabolites than RU. The relative bioavailability of 
total flavonols (sum of quercetin and its metabolites isorhamnetin, tamarixetin, and 
kaempferol) from RU was 72.5 % on d 2 and 49.6 % on d 29 when compared with QA 
(100 %). Calves fed QA reached maximum plasma concentrations of total flavonols 
much earlier than did RU-fed calves. Plasma metabolites and hormones were barely 
affected by QA and RU feeding in this experiment. Taken together, orally administrated 
QA resulted in a greater bioavailability of quercetin than RU on d 2 and 29, 
respectively, and differed markedly between calves aged 2 and 29 d.  
Key Words: bioavailability, calf, flavonoid, quercetin, rutin 
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2.1 Introduction  
Flavonoids are secondary plant metabolites occurring ubiquitously in all higher plants 
(Manach et al., 2004; Besle et al., 2010). They are known for their health-promoting 
properties (e.g. antioxidative and anti-inflammatory; Middleton et al., 2000; Nijveldt et 
al., 2001; Williams et al., 2004). Quercetin is one of the most abundant flavonoids and 
is present in high concentrations in onions, apples, and kale (Hertog et al., 1992; 
Nijveldt et al., 2001), and in low concentrations also in milk (Besle et al., 2010; 
Bhagwat et al., 2013). In addition to their health-promoting properties, quercetin and its 
metabolites modulate the expression and activity of several metabolic key enzymes, and 
therefore might be involved in regulation of lipid and carbohydrate metabolism 
(Middleton et al., 2000; Gasparin et al., 2003; Kobayashi et al., 2010).  
Newborn calves undergo tremendous immunological and metabolic changes after birth 
to adapt for extra-uterine life (Blum, 2006; Chase et al., 2008; Hammon et al., 2012) 
and colostrum management is one of the most important factors to support neonatal 
health and development (Godden, 2008; Hammon et al., 2012). Nevertheless, morbidity 
and mortality rates are still high during first weeks of life and calves often suffer from 
diarrhea and respiratory disease (McGuirk, 2008; Mee, 2008; Uetake, 2013) as well as 
from high levels of oxidative stress (Inanami et al., 1999; Gaál et al., 2006). Frequent 
problems on farms are the lack of high-quality colostrum availability and the 
insufficient colostrum supply (Quickley and Drewry, 1998; Godden, 2008). Colostrum 
and mature milk contain antioxidant agents to protect neonatal calves from oxidative 
stress (Lindmark-Månsson and Åkesson, 2000; Besle et al., 2010). Poor quality of 
colostrum is reflected by low concentrations of antioxidative substances. Thus, 
supplementing colostrum and milk at beginning of lactation with the natural antioxidant 
agent quercetin may improve neonatal oxidative status. However, there is no 
information about the bioavailability (BV) of orally applied quercetin with colostrum 
and milk in newborn calves, although feeding industry already offers flavonoid-
supplemented feed for dairy calves. 
Studies on BV of quercetin from quercetin aglycone (QA) or its glucorhamnoside rutin 
(RU) in different monogastric species, such as rats (Manach et al., 1997), pigs (Ader et 
al., 2000; Cermak et al., 2003; Lesser et al., 2004), dogs (Reinboth et al., 2010), and 
humans (Erlund et al., 2000; Egert et al., 2008), showed marked differences to ruminant 
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species (e.g. cows with intraruminal QA and RU application; Berger et al., 2012). These 
differences may be due to differnces in gastrointestinal anatomy and physiology (Arts et 
al., 2004; Berger et al., 2012; Gohlke et al., 2013). Conversely, in newborn calves the 
forestomach system is just developing, thus newborn calves are functionally 
monogastrics (Drackley et al., 2008). The aim of the present study was to investigate the 
relative BV of quercetin after oral administration of QA or RU in calves during first 
month of life. We hypothesized that BV in calves depends on the form of application 
(QA and RU) and changes with age due to ontogenetic development and maturation of 
the gastrointestinal tract during first month of life. We further tested the hypothesis that 
quercetin application might affect metabolic and endocrine traits, especially concerning 
glucose metabolism in neonatal calves, because findings in literature pointed to impair 
carbohydrate digestion and glucose absorption after flavonoid intake (Cermak et al., 
2004; Tadera et al., 2006).  
2.2 Materials and Methods 
2.2.1 Animals and feeding 
The experimental procedures were carried out according to the animal care guidelines 
and were approved by the relevant authorities of the State Mecklenburg-West 
Pomerania, Germany (LVL M-V/TSD/7221.3-2.1-019/10). Twenty-one male German 
Holstein calves were examined on d 2 and 29 of life. All calves were spontaneously 
born from multiparous cows on neighboring farms and transported directly after birth to 
the experimental barn. Calves were kept in single boxes with straw bedding and had 
free access to water. Calves were fed twice daily (0700 and 1500 h) with a nipple bottle 
or nipple bucket. On the first 3 d of life calves received pooled colostrum obtained from 
milkings 1, 3, and 5 (d 1, 2, and 3 after parturition, respectively; Table 2.1) at amounts 
of 8 % of BW on d 1 and 10 % of BW on d 2 and 3 (Steinhoff-Wagner et al., 2011). 
From d 4 until d 29, calves received milk replacer (150 g/L; SalvaLac MiraPro 45, 
Salvana Tiernahrung GmbH, Klein-Offenseth Sparrieshoop, Germany) at 12 % of 
BW/d (Table 2.1). To ensure uptake of equal amounts of feed, refused amounts of 
colostrum or milk were tube-fed to calves. Milk intake was adapted to BW data once a 
week.  
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Colostrum or milk replacer was supplemented with chicken egg-derived 
immunoglobulins (Globigen Life Start 25 %, EW Nutrition GmbH, Visbek, Germany) 
composed of 75 % dextrose and 25 % whole egg powder (10.75 % CP, 10.50 % crude 
fat, 0.10 % crude fiber, and 2.50 % ash) with high antibody titer against Eschericha coli 
type K 99, Salmonella Tymphimurium and Salmonella Dublin, bovine rotavirus type 
G6 and G10, bovine coronavirus, Cryptosporidium parvum, and Clostridium 
perfringens serotype C. Immunoglobulins were added from d 2 till d 6. Respective 
amounts of immunoglobulins fed twice daily were 40, 32, 24, 16, and 8 g/d.  
From d 4 on calves had free access to pelleted concentrate (Kälber Start 18/3 pell., 
Vollkraft Mischfutterwerke GmbH, Karstädt, Germany; Table 2.1) and hay. 
Concentrate intake was measured daily after morning milk feeding. To avoid iron 
deficiency, calves received 600 mg iron dextran subcutaneously (Ursoferran, 
Serumwerk Bernburg, Germany) on their first day of life. Navel disinfection was 
performed with 10 % iodine solution (vet sept Lösung, Albrecht GmbH, Aulendorf, 
Germany) immediately after birth. Health status of calves was determined daily by 
measuring rectal temperature, heart rate, and respiratory rate, by evaluation of 
behavioral abnormalities, nasal discharge, respiratory sounds, fecal consistence, and by 
navel inspection. 
2.2.2 Treatment and blood sampling 
Calves were randomly assigned to 1 of 3 feeding groups (n = 7 per group) receiving 
either no flavonoids (control group; CTRL), 9 mg of QA/kg of BW (quercetin aglycone 
dihydrate, Carl Roth GmbH, Karlsruhe, Germany), or 18 mg of RU/kg of BW (rutin 
trihydrate, Carl Roth GmbH), each resulting in a dose of 9 mg of quercetin equivalents 
(QE)/kg of BW on d 2 and d 29 of life. Calves received the whole dose of QA or RU 
during morning feeding, applying the QE suspension with a 10-ml syringe directly into 
the mouth.  
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The day before the study started, a catheter (Certofix Mono 340, Braun Melsungen AG, 
Melsungen, Germany) was inserted into the calves’ right jugular vein and blood 
samples were taken before (time point 0), and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, and 
48 h after feeding using S-Monovette tubes (Sarstedt AG & Co., Nümbrecht, Germany) 
containing lithium heparin (16 IU/mL blood) for analysis of plasma flavonols. 
Additional blood samples, except on 1.5, 2.5, and 48 h, were taken for measurement of 
plasma concentrations of total protein, albumin, glucose, NEFA, urea, and lactate using 
tubes containing sodium fluoride and K3EDTA (1.0 mg/mL fluoride and 1.2 mg/mL 
EDTA). Blood sampled into tubes containing dipotassium EDTA (1.8 mg/mL) was used 
for determination of insulin and cortisol plasma concentrations. Catheters were flushed 
with 10 mL sodium chloride solution (0.9 % sodium chloride, Braun Melsungen AG) 
after each blood sampling. Blood was immediately put on ice, centrifuged for 20 min at 
1,500 × g at 4° C, and plasma was stored at -80° C for flavonol analysis, and at -20° C 
for analyses of metabolites and hormones.  
2.2.3 Analytical methods 
Flavonols were extracted from plasma as described by Egert et al. (2008) and 
concentrations of quercetin aglycone and its methylated (isorhamnetin, tamarixetin) and 
dehydroxylated (kaempferol) derivatives were analyzed by HPLC with fluorescence 
detection as previously described (Ader et al., 2000; Berger et al., 2012; Gohlke et al., 
2013). Briefly, plasma samples were thawed in a 40° C water bath. Then 980 μL of 
plasma was acidified with 130 μL of acetic acid (0.583 mol/L), spiked with 20 μL of 
methanolic rhamnetin solution (internal standard, 1 mg/20 mL in methanol; Rotichrom 
HPLC, Carl Roth GmbH) and treated with a mixture of β-glucuronidase and sulfatase 
(from Helix pomatia Type H-1, with final activities of 7,300 and 130 U/mL for 
glucuronidase and sulfatase, respectively; Sigma-Aldrich Chemie GmbH, Dreieich, 
Germany) to cleave the ester bonds of glucuronides and sulfates. After incubation at 
37° C for 1 h, 3 mL of acetone was added and the samples were centrifuged at 3,700 × g 
for 45 min at 4° C). The supernatant was evaporated until dryness. Residues were 
resolved in 200 μL methanol, and after 15 min in an ultrasonic bath 77.5 μL of 
nanopure water and 22.5 μL of hydrochloric acid (10 mol/L) were added. For flavonol 
analyses by HPLC, 30 μL of the final solution was injected by a cooled (4° C) 
autosampler (AS-2057 Plus, Jasco Deutschland GmbH, Groß-Umstadt, Germany) onto 
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a C-18 Kromasil 100 column (250 × 4 mm, particle size = 5 μm, Jasco Deutschland 
GmbH) guarded by a pre-column (C-18 Inertsil ODS-2, 10 × 4 mm, particle size = 5 
μm, Jasco Deutschland GmbH). The eluent (flow rate: 1 mL/min) was composed of 
0.025 mol/L sodium dihydrogen phosphate (pH 2.4), acetonitrile, and methanol 
(68:27:5 vol/vol/vol). In a postcolumn reactor, the effluent was mixed with aluminum 
nitrate [flow rate = 0.4 mL/min, 1 mmol/L in methanol containing 7.5 % [vol/vol] acetic 
acid] for derivatization, and fluorescence of the flavonol-aluminum complex was 
measured using a fluorescence detector (excitation wavelength = 422 nm, emission 
wavelength = 485 nm; FP920, Jasco Deutschland GmbH). Identification of peaks 
obtained was performed using the retention times of the standards, which were prepared 
with pure flavonols and treated in the same way as samples. The detection limit of 
flavonols was ≤10 nmol/L and the recovery rate was 92 ± 2 % (mean ± SE). Inter- and 
intraassay variances for quercetin were 7.2 and 0.5 %. The sum of plasma 
concentrations of quercetin and its metabolites in plasma is referred to as total 
flavonols.  
Plasma metabolites were analyzed spectrophotometrically (ABX Penta 400; Horiba 
ABX SAS, Montpellier Cedex, France) by the Clinic for Cattle (University of 
Veterinary Medicine, Foundation, Hanover, Germany), using the respective kits: 
Albumin (no. A11A01664) and lactate (no. A11A01721; Horiba Europe GmbH, 
Hannover, Germany), NEFA (no. 434-91795; Wako Chemicals GmbH, Neuss, 
Germany), glucose (no. 553-230) and total protein (no. 553-412; MTI Diagnostics 
GmbH, Idstein, Germany), and urea (no. LT-UR 0050; Labor + Technik E. Lehmann 
GmbH, Berlin, Germany).  
Plasma insulin concentrations were determined using an RIA as previously described 
(Vicari et al., 2008). Plasma cortisol concentrations were analyzed using a commercial 
ELISA kit validated for bovine plasma (EIA-1887; DRG Instruments GmbH, Marburg, 
Germany; Weber et al., 2013). Cross reactivities of the monoclonal antibody against 
corticosteron and progesterone were 45 and 9 %, respectively, and to any further plasma 
steroids lower than 2 %. Test sensitivity was 3.4 ng/mL; inter- and intraassay variations 
were 5.3 and 12.1 %, respectively.  
Colostrum was analyzed for DM, CP, crude fat, and ash content (Qualitätsprüfungs- und 
Dienstleistungsgesellschaft Mecklenburg-Vorpommern mbH, Güstrow, Germany) 
according to the Weender standard procedure (Naumann and Bassler, 2004), as shown 
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in Table 2.1. Chemical composition of milk replacer and concentrates were according to 
the manufacturers’ declarations (Table 2.1).  
2.2.4 Calculations and statistical analyses 
Quercetin measurements were corrected by baseline concentration (first blood sample, 
before QA or RU administration), then area under the curve (AUC) was calculated for 
quercetin and its metabolites (isorhamnetin, tamarixetin, and kaempferol) according to 
the trapeziodale rule between 0 and 24 h using GraphPad Prism 3 (GraphPad Software 
Inc., San Diego, CA, version 3.03). For single quercetin metabolites, AUC proportion 
relative to AUC of total flavonols (sum of quercetin, isorhamnetin, tamarixetin, and 
kaempferol) was calculated in addition. Maximum plasma flavonol concentrations 
(Cmax) and time after intake until Cmax was reached (Tmax) were determined from 
individual plasma concentration-time curves. Relative BV of quercetin from RU was 
calculated as 
 Relative BV = AUCRU/AUCQA × 100 %.  
Statistical analyses were performed using SAS/STAT software (SAS Institute, 2010). 
All data are presented as LSM ± SE. Body weight, concentrate intake, and 
pharmacokinetic parameters (AUC, Cmax, Tmax) as well as proportions of single 
metabolites on d 2 and 29, were analyzed by repeated measurement ANOVA using the 
Mixed procedure with group (levels: CTRL, QA, RU; for proportional calculations only 
QA and RU), repeated variable day (levels: d 2, 29), and group × day interaction as 
fixed effects in the model. Repeated measures on each calf were taken into account by 
using the repeated statement of the Mixed procedure with an autoregressive residual 
covariance structure. Plasma concentration of total flavonols as well as metabolite and 
hormone data were analyzed by repeated measurement ANOVA using the Mixed 
procedure, as described previously, with group (levels: CTRL, QA, RU), day (levels: d 
2, 29), time changes within d 2 and 29 (several time points before and after feed intake 
on d 2 and 29, respectively), and respective interactions as fixed effects. Pairwise 
differences among treatments and time changes were tested by the Tukey-Kramer-test. 
Effects were considered significant if P < 0.05.  
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2.3 Results 
2.3.1 Body weight and feed intake 
All calves were born spontaneously and healthy. Birth weight was 47.4 ± 1.0 kg. Body 
weight increased with time in all groups (P < 0.01) and was 65.5 ± 1.3 kg on d 29 
without differences between groups. Milk intake was 3.8 ± 0.1 kg/d on d 1 (8 % of 
BW), 4.8 ± 0.1 kg/d on d 2 (10 % of BW), and 6.9 ± 0.1 kg on d 29. Concentrate intake 
was 1.59 ± 0.28 kg/calf and increased equally with time (P < 0.01) in all groups. 
Average daily gain from birth to d 29 was 612 ± 28 g/d without group differences. 
2.3.2 Bioavailability studies 
Plasma concentrations of total flavonols of CTRL were close to or below the detection 
limit on d 2 and 29, respectively (Figure 2.1A, B). In QA- and RU-fed calves plasma 
concentrations of total flavonols increased (P < 0.05) after flavonoid administration on 
d 2 and returned to baseline concentrations 48 h after administration (Figure 2.1A).  
 
Figure 2.1. Plasma concentration-time-curves of total flavonols after oral administration of 9 mg of 
quercetin/kg of BW × d as quercetin aglycone (), rutin trihydrate (), or no flavonoid (●) on d 2 
(A) and 29 (B) of life. Values are LSM ± SE, n = 7. 
On d 2, plasma concentrations of total flavonols were greater at 8 and 12 h (P < 0.01), 
but were smaller at 24 h after flavonoid administration (P < 0.01) in QA- than in RU-
fed calves. On d 29, postprandial plasma concentrations of total flavonols increased far 
less distinctly (P < 0.01) when compared to d 2 (Figure 2.1A, B). Further, plasma 
concentrations of total flavonols increased until 8 h after administration (P < 0.01) in 
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QA-, but not in RU-fed calves (Figure 2.1B). Plasma concentrations of total flavonols 
on d 29 tended to be greater (P < 0.1) in QA- than in RU-fed calves. 
Compared with QA- (100 %), RU-fed calves showed a relative BV of quercetin of 
72.5 % on d 2 and of 49.6 % on d 29. On d 2, AUC of total flavonols, quercetin, and 
quercetin metabolites in QA- and RU-fed calves differed (P < 0.05) from CTRL, and 
were greater (P < 0.001) on d 2 than on 29 for both treatments (Table 2.2). On d 2, AUC 
of quercetin and isorhamnetin was greater (P < 0.05) and tended to be greater for total 
flavonols (P < 0.1), but was lower for tamarixetin (P < 0.05) in QA- than in RU-fed 
calves. On d 29, AUC of quercetin was greater (P < 0.05) in QA-fed calves than in 
CTRL.  
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 Figure 2.2. Proportion of single flavonols (quercetin, isorhamnetin, tamarixetin, and kaempferol) 
in plasma after oral administration of 9 mg of quercetin/kg of BW × day as quercetin aglycone 
(QA) or rutin trihydrate (RU) on d 2 and 29 of life. Values are LSM ± SE, n = 7. 
On d 2, Cmax of total flavonols, quercetin, and quercetin metabolites except kaempferol 
of QA- and RU-fed calves differed from CTRL (P < 0.05; Table 2.2), whereas on d 29 
only Cmax of total flavonols and quercetin of QA-fed calves differed (P < 0.05) from 
CTRL. Maximal plasma concentrations of total flavonols, quercetin, and isorhamnetin 
decreased (P < 0.05) or tended to decrease (kaempferol, tamarixetin; P < 0.1) in QA- 
and RU-fed calves from d 2 to 29, respectively. On d 2, Cmax was greater (P < 0.05) for 
quercetin and isorhamnetin, but was lower for tamarixetin in QA- than in RU-fed 
calves. Time to reach Cmax in QA- and RU-fed calves was not affected by day, but 
indicated treatment effects for total flavonols, isorhamnetin, and tamarixetin (Table 
2.2). For isorhamnetin, Tmax was greater (P < 0.05) in RU- than in QA-fed calves on 
both days.  
  CHAPTER 2 
 
 62   
Table 2.2. Pharmacokinetic parameters after oral administration of quercetin as quercetin 
aglycone (QA) or rutin trihydrate (RU) on d 2 and 29 of life; calves of the control group (CTRL) 
received no flavonoids. 
Item
1
 Day 
Group
2
 
  SE 
ANOVA (P-value) 
CTRL   QA   RU Group Day 
Group  
× day 
AUC 
3
, nmol/L × h        
AUCTotal    2    154
c
 5947
a
 4312
ab
 395 0.001 0.001 0.001 
  29        7.70 1336   662     
AUCQ    2    102
c
 3413
a
 1967
b
 228 0.001 0.001 0.001 
  29      26.7
b
 1090
a
   535
ab
     
AUCK    2      31.9
b
   152
a
   159
a
  24.4 0.02 0.001 0.05 
  29        0.00    11.1      6.39     
AUCI    2        0.00
c
 1390
a
   447
b
  70.1 0.001 0.001 0.001 
  29        0.00     67.5   239     
AUCT    2       0.00
c
 1070
b
 1768
a
 154 0.001 0.001 0.001 
  29       0.00     58.3    19.6     
Cmax
4
, nmol/L        
Cmax, Total    2     13.9
b
   407
a
  330
a
  35.9 0.001 0.001 0.001 
 29       2.24
b
   168
a
    74.7
ab
     
Cmax, Q    2     10.7
c
   238
a
  129
b
  19.3 0.001 0.001 0.03 
  29       6.28
b
   137
a
    60.3
ab
     
Cmax, K    2       1.96
b
    12.4
a
    10.9
ab
    2.07 0.01 0.001 0.16 
  29       0.00      3.86      2.12     
Cmax, I    2       0.00
c
    94.5
a
    39.6
b
    5.85 0.001 0.001 0.001 
  29       0.00    15.5      3.99     
Cmax, T    2       0.00
c
    77.1
b
   163
a
  15.6 0.001 0.001 0.001 
  29       0.00      9.45      3.27     
Tmax
5
, h         
Tmax, Total    2       9.50    10.6    16.4    2.84 0.05 0.12 0.90 
  29       6.49      6.21    10.4     
Tmax, Q    2       6.65      8.86    11.7    2.77 0.31 0.47 0.76 
  29       6.44      5.93    11.1     
Tmax, K    2     10.0      9.67    12.3    4.01 0.93 0.49 0.76 
  29 ND
6
      8.00      8.00     
Tmax, I    2 ND    11.4
b
    19.3
a
    2.56 0.001 0.88 0.09 
  29 ND      5.90
b
    24.0
a
     
Tmax, T    2 ND    11.1    16.6    3.57 0.01 0.63 0.18 
  29 ND      7.63    24.0     
a-c
LSM in a row with different superscripts differ (P < 0.05).  
1
Values are LSM with SE, n = 7 per group.  
2
Group: QA = 30 µmol/(kg BW × d) quercetin aglycone, RU = 30 µmol/(kg BW × d) rutin trihydrate, 
CTRL = no flavonol fed. 
3
AUC = area under the plasma concentration-time curve of flavonols from 0 to 24 h, calculated by 
subtracting baseline values (time point 0) from all other time points according to the trapezoidale rule; 
AUCTotal, AUCQ, AUCK, AUCI, AUCT = AUC of total flavonols (Total) or of the respective quercetin 
metabolites quercetin (Q), kaempferol (K), isorhamnetin (I), and tamarixetin (T), respectively.  
4
Cmax = maximum plasma concentration of flavonols subtracted by basal plasma concentration before feed 
intake; Cmax, Total, Cmax, Q, Cmax, K, Cmax, I, Cmax, T = maximum plasma concentration of total flavonols 
(Total), quercetin aglycone (Q), kaempferol (K), isorhamnetin (I), and tamarixetin (T), respectively. 
5
Tmax = time until Cmax was reached; Tmax, Total, Tmax, Q, Tmax, K, Tmax, I, Tmax, T = time until Cmax, Total, Cmax, Q, 
Cmax, K, Cmax, I, Cmax, T was reached, respectively. 
6
ND = Not definable. 
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Relative distribution of single flavonols (quercetin, isorhamnetin, tamarixetin, and 
kaempferol) proportionately to total flavonols in plasma showed highest values for 
quercetin on both days and in both groups (QA and RU). Proportion of single flavonols 
changed with time, namely increased for quercetin (P < 0.05) but decreased for 
isorhamnetin and tamarixetin (P < 0.05) from d 2 to 29 (Figure 2.2A, B). On d 2, 
proportion of isorhamnetin was greater (P < 0.05) and proportion of tamarixetin was 
smaller (P < 0.05) in QA- than in RU-fed calves (Figure 2.2A). 
2.3.3 Plasma concentrations of metabolites and hormones 
Plasma concentrations of total protein decreased (P < 0.05) from d 2 to 29 in CTRL and 
were greater on d 2 in CTRL than in QA-fed calves (P < 0.05; Table 2.3). Plasma 
concentrations of albumin increased (P < 0.01) and plasma concentrations of lactate and 
urea decreased (P < 0.01) from d 2 to 29 without any group effect (Table 2.3).  
 
Table 2.3. Blood plasma concentrations of metabolites and hormones of calves after oral 
administration of quercetin as quercetin aglycone (QA), rutin trihydrate (RU), or no flavonoid 
(CTRL) on d 2 and d 29. 
Item
1
 Day 
Group
2
 
SE 
ANOVA (P-value)  
CTRL QA RU Group Day 
Group  
× day 
Total 
protein, g/L 
   2   64.0
a
   59.9
b
   61.7
ab
   0.98 0.03 0.001    0.07 
 29   58.0   56.5   59.6  
Albumin, 
g/L 
   2   22.9   22.6   22.5   0.37 0.95 0.001    0.42 
 29   26.1   26.5   26.3 
Lactate, 
mmol/L 
   2     1.68     2.37     2.65   0.27 0.31 0.001    0.04 
 29     0.63     0.68     0.69    
Glucose, 
mmol/L 
   2     7.37     7.14     7.61   0.28 0.35 0.001    0.99 
 29     6.58     6.40     6.79 
NEFA, 
µmol/L 
   2 298 281 298 13 0.87 0.001    0.65 
 29 172 177 173    
Urea, 
mmol/L 
   2     3.80     3.75     3.55   0.26 0.91 0.001    0.82 
 29     1.55     1.56     1.55 
Insulin, 
µg/L 
   2     2.38     1.79     2.41   0.65 0.12 0.08    0.29 
 29     4.38     2.09     2.77 
Cortisol,     2   67.2   62.9   77.9   7.0 0.43 0.001    0.67 
nmol/L  29   11.1     8.6   13.0    
a-b
LSM in a row with different superscripts differ (P < 0.05).  
1
Values are LSM based on plasma concentrations in blood samples taken before and until 24 h after 
morning feeding on d 2 and 29, respectively; n = 7 per group.
 
2
Group: QA = 30 µmol/(kg BW × d) quercetin aglycone; RU = 30 µmol/(kg BW × d) rutin trihydrate; 
CTRL = no flavonol fed.  
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Figure 2.3. Plasma concentrations of glucose (A, B) and NEFA (C, D) after oral administration of 9 
mg of quercetin/kg BW × d as quercetin aglycone (), rutin trihydrate (), or no flavonoid (●) on 
d 2 and d 29 of life. Values are LSM ± SE; n = 7.  
Mean glucose and NEFA plasma concentrations decreased (P < 0.05) from d 2 to 29 in 
all groups, but concentrations did not differ among groups (Table 2.3). Considering the 
day course of the plasma metabolites, plasma concentrations of glucose increased (P < 
0.01), whereas NEFA decreased (P < 0.01) after feed intake in all groups on d 2 and 29, 
respectively (Figure 2.3A-D).  
The increase of plasma insulin concentrations after feed intake was more pronounced (P 
< 0.05) on d 29 than on d 2, but without group effects (Figure 2.4A, B; Table 2.3). 
Plasma concentrations of cortisol decreased (P < 0.05) after feed intake on both days 
with mean concentrations being greater (P < 0.05) on d 2 than on d 29 (Figure 2.4C, D; 
Table 2.3).  
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Figure 2.4. Plasma concentrations of insulin (A, B) and cortisol (C, D) after oral administration of 9 
mg of quercetin/kg of BW × d as quercetin aglycone (), rutin trihydrate (), or no flavonoid (●) 
on d 2 and d 29 of life. Values are LSM ± SE, n = 7.  
2.4 Discussion 
Without dietary supplementation of quercetin (CTRL group) plasma concentrations of 
total flavonols were close to or below the detection limit on d 2 and 29. However, small 
amounts of quercetin and its dehydroxylated metabolite kaempferol were found in blood 
plasma on d 2 and 29 in the control group. According to Besle et al. (2010), flavonoids 
are natural components of bovine milk and their concentration is affected by cow’s diet. 
Although colostrum and milk replacer were not analyzed for flavonoid content in the 
present study, it can be assumed that colostrum is most likely the source for flavonoids 
found in CTRL calves at d 2. Apart from colostrum, feed components such as 
concentrates and hay may also contain flavonoids (Fraisse et al., 2007; Reynaud et al., 
2010), which could explain measurable, albeit very low, plasma concentrations of 
quercetin and its metabolites at least in older calves (d 29).  
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In calves, quercetin was systemically available from both supplements, QA as well as 
RU. Interestingly, plasma values obtained for quercetin and its metabolites with an 
intact flavonol structure were greater on d 2 than on d 29, indicating better absorption or 
less excretion in younger animals. This may be explained by a different degree of 
gastrointestinal maturation and intestinal permeability on d 2 and 29, respectively 
(Blum, 2006). Thus, the epithelium in newborn animals is characterized by vacuolated 
epithelial cells which are not present in older animals (Bainter, 2002; Blum, 2006). This 
has possibly contributed to a greater absorption of quercetin from both sources (QA and 
RU) on d 2 compared with d 29 in calves. Furthermore, the reticulorumen and microbial 
activities might be already more developed in 29- than in 2-d-old calves, resulting in 
partial ruminal degradation of the flavonoids applied (Heinrichs and Jones, 2003; 
Guilloteau et al., 2009; Berger et al. 2012; Li et al., 2012). The BV of quercetin from 
both, QA and RU, especially on d 29 could probably be improved when encapsulated 
quercetin preparations will be used (Ding et al., 2014).  
On both days investigated, feeding of QA resulted in greater plasma concentrations of 
total flavonols, quercetin, and its metabolites than feeding of RU, indicating QA as a 
better source of quercetin than RU with respect to the BV of quercetin. Markedly lower 
plasma concentrations of total flavonols were also seen in monogastric species after 
feeding of RU instead of QA at dosages comparable to the current study (Manach et al., 
1997; Cermak et al., 2003; Reinboth et al., 2010). Thus, the present results obtained in 
calves are in principal accordance with studies on the BV of quercetin in monogastric 
species such as rats (Manach et al., 1997), dogs (Reinboth et al., 2010), pigs (Cermak et 
al., 2003; Lesser et al., 2004), and humans (Erlund et al., 2000; Egert et al., 2008). As 
the newborn calf is considered as a functionally monogastric animal (Drackley, 2008), 
these findings are not surprising.  
Concerning RU application, studies in monogastric species often indicate a delayed 
increase of quercetin and its metabolites in blood plasma (Erlund et al., 2000; Cermak et 
al., 2003; Reinboth et al., 2010). In the present study, maximal plasma concentrations of 
quercetin and its metabolites were measured much later after RU than after QA feeding, 
indicating different intestinal sites for absorption (Erlund et al., 2000). In RU-fed 
calves, quercetin and its metabolites, at least on d 2, most likely derive from absorption 
in both the small and the large intestine. In addition, we found the same slow increase of 
quercetin and its metabolites in blood plasma after QA and RU feeding, but the increase 
  CHAPTER 2 
 
 67   
stopped much earlier in RU- than in QA-fed calves. In general, the sugar moiety in 
flavonol molecules determines the absorption of flavonoids in organisms (Day et al., 
1998; Hollman et al., 1999) and QA is supposed to be already absorbed in the small 
intestine. More complex glycosides, such as the glucorhamnoside RU, are absorbed in 
distal parts of the small intestine or in the colon of monogastric animals, where flavonol 
molecules are hydrolyzed by microorganisms. Thus, the lack of rhamnosidase activity 
in the small intestine can be considered as one reason for delayed and lower absorption 
of RU than of QA (Erlund et al., 2000; Cermak et al., 2003). Our pattern of relative BV 
of total flavonols after RU feeding fits to relative BV of total flavonols in blood plasma 
after duodenal, but not after ruminal application in dairy cows (Berger et al., 2012; 
Gohlke et al., 2013), indicating a low ruminal function in our calves during first month 
of life. 
Interestingly, pharmacokinetics of quercetin absorption after QA feeding markedly 
differed between calves and adult cattle (Berger et al., 2012; Gohlke et al., 2013) or 
monogastric animals (Erlund et al., 2000; Cermak et al., 2003; Reinboth et al., 2010). 
The typical peak of total flavonol plasma concentrations some minutes after QA 
administration was not seen in newborn calves. As a consequence, time for reaching 
Cmax was much greater in calves than in adult ruminants and monogastrics. Comparable 
slow increases of quercetin and its metabolites as in newborn calves’ blood plasma were 
only seen in rats (Manach et al., 1997). These differences in pharmacokinetics after QA 
feeding are difficult to explain, but a probable reason is the low release of milk protein 
into the duodenum due to abomasal casein clotting (Heinrichs and Jones, 2003; 
Guilloteau et al., 2009) and the potential binding of flavonoids to milk proteins (Gugler 
et al. 1975; Boulton et al., 1998; Janisch et al., 2004).  
All measured metabolites and hormones were in physiological ranges and most of these 
findings were in accordance with previous results indicating postnatal growth, 
especially protein accretion, and development in breeding as well as suckling calves 
(Egli and Blum, 1998; Nussbaum et al., 2002; Schiessler et al., 2002). Conversely, 
except for total protein concentrations on d 2, we found no treatment effects by QA or 
RU feeding in these calves. Plasma protein concentrations were lower in QA-fed than in 
CTRL calves, a finding that was hard to explain because all calves received the same 
pooled colostrum with identical IgG content at first days of life. Postprandial changes of 
metabolites and hormones have been reported previously (Hadorn et al., 1997; Hammon 
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and Blum, 1998), but systemic glucose metabolism was not affected by QA or RU 
feeding, as we have assumed from literature (Cermak et al., 2004; Tadera et al., 2006).  
In conclusion, BV of quercetin and its metabolites in newborn calves is more 
pronounced when quercetin is fed as QA than as RU. These findings go along with data 
on BV of quercetin in lactating cows with duodenal application (Gohlke et al., 2013), 
and in monogastric species like rats, dogs, and pigs (Manach et al., 1997; Cermak et al., 
2003; Reinboth et al., 2010). Greater BV of quercetin on d 2 than on d 29 of life was 
probably due to reduced maturation status of the gastrointestinal tract in 2-d old calves. 
However, effects of quercetin feeding on the antioxidative status should be investigated 
to validate health-protecting effects of quercetin in neonatal calves.  
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3. Effects of oral flavonoid supplementation on metabolic and 
antioxidative status in newborn dairy calves 
Abstract 
Many studies investigated effects of natural feed additives like flavonoids and verified 
their antioxidative or antiinflammatory properties, but scientific proof for flavonoids as 
health and performance-promoting tool in calf nutrition is weak. Thus, we investigated 
the effects of the most abundant flavonoid quercetin and of a green tea extract (GTE) 
containing various catechins on metabolic and antioxidative traits in dairy calves to 
further clarify potential health-promoting effects. Male newborn German Holstein 
calves (n=7 per group) either received no flavonoid (control group), 10 mg of quercetin 
equivalents as quercetin aglycone or as rutin/kg of body weight (BW) and d, or 10 
mg/kg BW and d of a GTE from d 5 to d 26 of life with morning and evening feeding. 
All calves were fed equal amounts of colostrum and milk replacer according to BW. 
Body Weight, feed intake, and health status were evaluated daily. Blood samples were 
collected from the jugular vein on d 1, 5, 12, 19, and 26 before morning feeding to 
investigate flavonoid, metabolic, and antioxidative status in calves. During the 
experiment, growth performance data and health status remained unchanged, but GTE-
fed calves had less loose feces than controls and calves fed quercetin aglycone required 
less medical treatment than other groups. Concentrations of quercetin changed over 
time and were higher in rutin-fed than control group, whereas catechins were below 
detection limit. Plasma trolox equivalent antioxidative capacity (TEAC) and ferric 
reducing ability of plasma (FRAP) were measured as markers for plasma antioxidative 
capacity. Concentrations of TEAC increased whereas FRAP decreased after the first d 
of life in all groups, least in controls. Oxidative stress markers in plasma were measured 
as thiobarbituric acid reactive substances (TBARS) and F2-isoprostances. 
Concentrations of TBARS were highest during first month of life in the control group, 
but decreased at the same time in the GTE group. F2-isoprostane concentrations 
decreased in control group only. Plasma concentrations of total protein, albumin, urea, 
lactate, glucose, and non-esterified fatty acids as well as of insulin and cortisol varied in 
time, but there were no group differences caused by flavavonoid supplementation. 
Taken together, orally administrated quercetin and catechins at dosages used in the 
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present study resulted in no or only weak effects on health, metabolic, and antioxidative 
status in newborn dairy calves.  
Key Words: antioxidative status, calf, flavonoid, quercetin, rutin 
3.1 Introduction 
After birth, calves undergo huge immunological and metabolic changes. Though 
relatively mature at birth, they need to adapt to various morphological and functional 
changes after birth (Blum and Hammon, 2000). Calf losses mainly occur during first wk 
of life, mostly because of respiratory and digestive problems (USDA, 2011). Good 
management, like early and sufficient colostrum supply is essential. In addition, fed 
supplements are daily practice in modern dairy. Particularly since the ban of antibiotic 
growth promoters in the European Union in 2006, the call for ʻnaturalʼ feed additives 
gained enormous popularity. In this respect, flavonoids as secondary plant metabolites, 
ubiquitous in all higher plants are of interest. Their health-promoting properties are 
mainly thought to be due to their strong antioxidant activity in vitro, associated with 
effects on several metabolic key enzymes and inflammatory cells (Middleton et al., 
2000), glucose and lipid metabolism (Shetty et al., 2004; Kobayashi et al., 2010) or 
incidence of diarrhea (di Carlo et al., 1994; Gálvez et al., 1995). One of the most 
abundant flavonoids is the flavonol quercetin, a pentahydroxyflavon mostly bound β-
glycosidic manner to at least one sugar molecule and present in high concentrations in 
apples and onions. Quercetin bound to rutinose is called rutin and is the major glycoside 
of quercetin. The predominant flavanol, another subgroup of flavonoids, is catechin, 
which is mainly found in high concentrations in green tea.  
Almost any disease is associated with increased formation of reactive oxygen species, 
thus causing oxidative stress (Halliwell, 1991). In calves, enhanced oxidative stress was 
seen on the first d of life (Alexandrovich and Antonovna, 2009) and especially if sick 
(Ahmed and Hassan, 2007; Al-Qudah, 2009). Because the nutrient status often is 
impaired in newborn calves, this possibly affects the antioxidant system (Schwerin et 
al., 2002; Sies et al., 2005). Thus, improvement of the antioxidant status in newborn 
calves may accelerate maturation of the own immune system, improve health status, and 
thus reduce calf losses. The bioavailability of quercetin in newborn calves as 
prerequisite for biological effects was recently shown (Maciej et al., 2015). Based on 
these findings we have tested the hypothesis that quercetin and catechin 
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supplementation affect metabolism and the antioxidative and health status during the 
first 3 wk of life in dairy calves. 
3.2 Materials and Methods  
3.2.1 Animals and feeding 
Procedures performed in this study were in accordance with the German animal 
protection law and approved by the relevant authorities (Landesamt für Landwirtschaft, 
Lebensmittelsicherheit und Fischerei, Mecklenburg-Vorpommern, Germany; 
permission no. LVL M-V/TSD/7221.3-2.1-019/10). Twenty-eight male German 
Holstein calves were examined from d 1 to d 26 of life. All calves were spontaneously 
born from multiparous cows on neighboring farms and transported directly after birth to 
the experimental barn of the University of Rostock, where they were kept in single 
boxes with straw bedding. Calves had free access to water and were fed twice daily by 
nipple bottle or nipple bucket. On the first 3 d of life calves received pooled colostrum 
obtained from milkings 1, 3, and 5 (d 1, 2, and 3 after parturition, respectively) in 
amounts of 8 % of BW on d 1 and 10 % of BW on d 2 and 3 (Table 1). From d 4 until d 
26 calves received a commercial milk replacer (150 g/L; SalvaLac MiraPro 45, Salvana 
Tiernahrung GmbH, Klein-Offenseth Sparrieshoop, Germany) in amounts of 12 % of 
BW/d. To ensure equal feed uptake in all groups refused amounts of colostrum or milk 
replacer were tub- fed. Milk replacer amounts were adapted to BW once a wk.  
From d 2 to d 6, colostrum or milk replacer was supplemented with chicken-egg derived 
immunoglobulins (Globigen Life Start 25 %, EW Nutrition GmbH, Visbek, Germany) 
fed twice daily in amounts of 40, 32, 24, 16, and 8 g/d, respectively (Maciej et al., 
2015).  
Calves had free access to pelleted concentrate (Kälber Start 18/3 pell., Vollkraft 
Mischfutterwerke GmbH, Karstädt, Germany) and hay from d 4 on. Concentrate intake 
was measured daily after the morning milk feeding (Maciej et al., 2015).  
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Health status of calves was determined daily by measuring rectal temperature, heart and 
respiratory rate, by evaluation of behavioral abnormalities, nasal discharge, respiratory 
sounds, and by navel inspection. Fecal consistence was assessed daily by fecal 
consistence score according to Larson et al. (1977): normal (1), soft (2), runny (3), or 
watery (4). Sick calves were treated by a veterinarian; for statistical analysis each calf 
was counted as treated for a disease independent from how many times an animal was 
treated. 
3.2.2 Treatment and blood sampling 
Calves were randomly assigned to one of four feeding groups (n = 7). Control (CTRL) 
received no flavonoids, QA received 10 mg/kg BW × d quercetin aglycone (quercetin 
dihydrate; Carl Roth GmbH & Co. KG, Karlsruhe, Germany), RU received 20 mg/kg 
BW × d quercetin as glucorhamnoside rutin (rutin trihydrate; Carl Roth GmbH & Co. 
KG), and CA received 10 mg/kg BW × d of a green tea extract (GTE) containing 
various catechins (Polyphenon 60; Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany). For QA and RU, daily dose of quercetin equivalents was 10 mg/kg of BW 
(30 µmol/kg BW). The GTE (70.3 % total catechins) fed in CA was composed of 1.4 % 
catechin, 0.3 % catechin gallate, 5.2 % gallocatechin, 2.1 % gallocatechin gallate (all as 
trans-isomers) and 6.4 % epicatechin, 7.0 % epicatechin gallate, 19.0 % 
epigallocatechin, 28.8 % epigallocatechin gallate (all as cis-isomers). Amounts of 
flavonoid fed to calves in this study were based on previous studies in pigs and dogs 
(Lesser et al., 2004; Reinboth et al., 2010; Lühring et al., 2011). Due to studies on 
bioavailability of flavonoids, all calves received their respective daily dose with the 
morning feeding on d 2, and no flavonoids were fed on d 3 and 4. From d 5 on, the daily 
dose was equally split with morning and evening meal since d 26. On d 1, 3, and 4 no 
flavonoids were fed. Flavonoids were suspended in water and administered with a 
disposable 10-ml syringe directly into the mouth during milk feeding.  
Jugular blood samples were taken immediately after birth, and on d 5, 12, 19, and 26 
before morning feeding using evacuated tubes (Vacuette; Greiner Bio-One GmbH, 
Frickenhausen, Germany). Tubes containing 15 I.U./mL lithium heparinate were used 
for the determination of the plasma concentrations of flavonols, catechins, and the 
markers for antioxidative capacity and oxidative stress; tubes containing 2.5 g/L sodium 
fluoride and 1.8 g/L potassium EDTA were used for the determination of plasma 
CHAPTER 3 
 
 82   
protein, albumin, glucose, NEFA, urea, and lactate, and tubes containing 1.8 g/L 
potassium-EDTA were used for the determination of plasma insulin and cortisol 
concentrations. The blood samples were immediately put on ice and centrifuged (1,500 
× g, 4°C, 20 min). To measure the catechins 1 mL of plasma was mixed with 20 µL of 
an ascorbate-EDTA solution (0.4 mol/L NaH2PO4; Carl Roth GmbH & Co. KG) 
containing 20 % ascorbic acid (Merck KGaA, Darmstadt, Germany) and 0.1 % EDTA 
(Carl Roth GmbH & Co. KG) at pH 3.6. To measure F2-Isoprostanes, a 0.005 % 
ethanolic butylhydroxytoluene (BHT) solution (0.005 % BHT in ethanol, w/v) was 
added in one percent proportion for stabilization. The plasma samples were stored until 
analyzed at -20°C for metabolites and hormones and at -80°C for flavonoid and 
(anti)oxidative parameters until analyzed.  
3.2.3 Analytical methods 
Plasma concentrations of quercetin aglycone and its methylated (isorhamnetin and 
tamarixetin) and dehydroxylated (kaempferol) derivatives were analyzed by HPLC with 
fluorescence detection as described previously (Berger et al., 2012). The detection limit 
of flavonol was ≤ 10 nmol/L and the recovery rate of flavonols was 92 ± 2 % (mean ± 
SEM). Inter- and intraassay coefficients of variability for quercetin were 7.2 and 0.5 %, 
respectively. The sum of quercetin and its metabolites in plasma is referred to as total 
flavonols.  
Plasma concentrations of individual catechins (gallocatechin, epigallocatechin, 
epigallocatechin gallate, epicatechin gallate, and epicatechin) were determined by 
HPLC (Lee et al., 1995) with some modifications (Egert et al., 2013). In brief, 500 µL 
of thawed plasma were mixed with 37.5 µL of β-glucuronidase/sulfatase (final activities 
of 7,300 and 130 U/mL for glucuronidase and sulfatase, respectively; Sigma Aldrich 
Chemie GmbH), and incubated at 37°C for 45 min. Hydrolyzation was stopped by 
adding 1 mL methylene chloride. Samples were mixed for 4 min and centrifuged (3,220 
× g, 4°C, 15 min). The supernatant was transferred into another tube, mixed with 1 mL 
ethyl acetate for 4 min, and centrifuged (3,220 × g, 4°C, 20 min); and 800 µL of the 
supernatant were transferred into a glass tube with glass pearls and ethyl acetate 
extraction was repeated twice. Supernatants were combined, mixed with 10 µL of 1 % 
aqueous ascorbic acid, and dried by vacuum centrifugation (SPD2010 SpeedVac 
System; Thermo Fischer Scientific GmbH, Dreieich, Germany). The dried sample was 
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dissolved in 150 µL of the mobile phase A by vortex mixing and ultrasonic bath for 15 
min. After centrifugation 30 µL of the supernatant were used for HPLC analyses. For 
catechin analyses by HPLC (Jasco Deutschland GmbH, Groß-Umstadt, Germany; pump 
model PU-2080 plus), the supernatant was injected into the fully automated autosampler 
(AS-2057 Plus; Jasco Deutschland GmbH). Separation occurred on a reverse-phase C-
18 Kromasil 100 column (25 × 4.6 mm, 5 µm; Jasco Deutschland GmbH) protected by 
a pre-column (C-18 Inertsil ODS-2, 10 × 4 mm, particle size 5 μm; Jasco Deutschland 
GmbH) at 30°C. Mobile phase A and B were composed of water, acetonitrile, and 
trifluoroacetic acid (92:8:0.1 and 65:35:0.1 v/v/v) with a pH of 2.5. At a flow rate of 0.9 
mL/min, the eluent was monitored by electrochemical detection with potential settings 
at 0, 120, 240, and 360 mV in a 4-channel colometric electrochemical detector (Coul 
Array, 5600A; ESA Inc., Chelmsford, MA). Dominant signals used for quantification of 
catechins were 120 mV for epigallocatechin and epicatechin gallate, and 240 mV for 
catechin, gallocatechin, epicatechin, and epigallocatechin gallate, respectively. 
Quantification of individual plasma catechins were carried out using external standards, 
which were generated by simultaneously adding catechin, gallocatechin, 
epigallocatechin, epigallocatechin gallate, epicatechin gallate, and epicatechin (Carl 
Roth GmbH & Co. KG) to untreated plasma at final concentrations of each catechin of 
0.125, 0.25, 0.5, 1, 2.5, 5, 7.5, and 10 µmol/L. Calibration samples were treated in the 
same way as experimental samples. The coefficient of determination was r ≥ 0.99, 
detection limit of catechins was ≤ 10 nmol/L, and the intra-assay coefficient of variation 
was 2.4 ± 2.6 to 6.5 ± 4.7 %.  
Antioxidative capacity and oxidative stress markers were analyzed in repeated 
measurements. The trolox equivalent antioxidative capacity (TEAC) is defined as 
amount of the water-soluble vitamin E derivate trolox (in mmol) needed to show the 
same antioxidant capacity at a defined time point as 1 mmol of plasma and is expressed 
as trolox equivalents (TE) in mmol/L plasma. The TEAC was measured according to 
the modified protocol of Re et al. (1999) by measuring spectrophotometrically the 
decolorization of 2,2'-azinobis(3-ethylbenzothiazoline-6-sulphonic acid) radical cation 
(ABTS·+) caused by binding to antioxidants at a wavelength of 734 nm. Ferric reducing 
ability of plasma (FRAP) was determined according to Benzie and Strain (1996) and is 
given in ascorbic acid equivalents (ASCE) in µmol/mL plasma. Reduction of Fe
3+
 - 
tripyridyltriazin by antioxidants from plasma results in a color change that is directly 
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proportional to antioxidative capacity. Absorbance was measured at a wavelength of 
595 nm and compared to the one of ascorbic acid. Thiobarbituric acid reactive 
substances (TBARS) concentration in plasma was measured according to Yagi (1998) 
with modifications and is given as malondialdehyde equivalents (MDAE) in µmol/L 
plasma. Adding thiobarbituric acid to the sample results in formation of a red complex, 
whose optical density was measured photometrically at a wavelength of 532 nm. F2-
isoprostanes, especially their main representative 8-iso-prostaglandin F2α, are produced 
in vivo by peroxidation of the cell membrane lipid component arachidonic acid, and is 
considered as a reliable marker for lipid peroxidation. Detection of 8-iso-prostaglandin 
F2α was carried out with an enzymatic immune assay (Direct 8-iso-prostaglandin F2α; 
Assay Designs, MI) and values are expressed in pg/mL.  
Plasma metabolites were analyzed by the Clinic for Cattle (University of Veterinary 
Medicine Hannover, Foundation, Germany) spectrophotometrically on an ABX Pentra 
400 (Horiba ABX SAS, Montpellier Cedex, France) using the respective kits: Albumin 
(no. A11A01664) and lactate (no. A11A01721; Horiba Europe GmbH, Hannover, 
Germany), NEFA (no. 434-91795; Wako Chemicals GmbH, Neuss, Germany), glucose 
(no. 553-230) and total protein (biuret reaction, no. 553-412; MTI Diagnostics GmbH, 
Idstein, Germany), and urea (no. LT-UR 0050; Labor + Technik E. Lehmann GmbH, 
Berlin, Germany). Plasma insulin and cortisol concentrations were measured either by 
radioimmunoassay or by ELISA, respectively, as previously described (Maciej et al., 
2015).  
Colostrum was analyzed for DM, CP, crude fat, and ash content (were measured by 
MQD Qualitätsprüfungs- und Dienstleistungsgesellschaft Mecklenburg-Vorpommern, 
Güstrow, Germany) using standard procedures according to Weende (Naumann and 
Bassler, 2004). Chemical components and contents of the milk replacer were provided 
by the manufacturer according to Weender analysis (Naumann and Bassler, 2004; Table 
3.1).  
3.2.4 Statistical analyses 
Statistical analyses were performed using SAS software, Version 9.4 for Windows. 
Copyright, SAS Institute Inc., Cary, NC, USA. Data on health, performance, and from 
plasma measurements are presented as least squares means (LSM) ± standard error (SE) 
and were analyzed by repeated measurement ANOVA using the Mixed procedure of 
CHAPTER 3 
 
 85   
SAS/STAT software with a model containing the fixed effects treatment group (levels: 
CTRL, QA, RU, CA; for plasma flavonol concentrations only CTRL, QA, RU), day 
(levels: 1, 5, 12, 19, 26) and group × day interaction. Repeated measures on the same 
animal were taken into account by the REPEATED statement of the MIXED procedure 
and an autoregressive type for the block diagonal residual covariance matrix. Pairwise 
differences among treatment groups and days were tested by the Tukey-Kramer-test. 
Data on fecal score and medical treatment were analyzed with the NPAR1WAY 
procedure of SAS/STAT software across the one-way classification treatment group 
(levels: CTRL, QA, RU, CA) using Wilcoxon scores (for each wk seperately). Effects 
and differences were considered significant if P < 0.05. 
3.3 Results  
3.3.1. Body weight, feed intake, and health status 
All calves were born spontaneously and were evidently healthy. Body weight was 47.3 
± 1.0 kg at birth, and did not differ among groups.  
Average daily gain (616 g/d ± 25 g; n = 28) and final BW (58.2 kg ± 0.42 kg, n = 28) 
was not different between groups.  
Milk intake increased with time (wk 1 = 5.1 kg/d; wk 2 = 6.1 kg/d, wk 3 = 6.4 kg/d, wk 
4 = 7.0 kg/d; P < 0.001) equally in all groups. Concentrate intake also increased with 
time (P < 0.001) equally in all groups. During the first wk concentrate intake was very 
low (4 g/d), but increased to 27 g/d during the second wk and to 117 g/d in wk 4.  
Average fecal score for all groups was 1.4 and each calf had on average 2 d of strong 
diarrhea, indicated by fecal score 4. Severe diarrhea occurred between d 3 and d 20, and 
fecal score was highest in wk 2 (fecal score 1.62) and wk 3 (fecal score 1.54). During 
the first wk of life, fecal score differed among groups, being lower (P < 0.05) in CA 
group (fecal score 1.01) than in CTRL group (fecal score 1.46) and in group QA (fecal 
score 1.31). 
Treatments of diseases showed no significant group differences. However, group CA 
had 3 treated calves (total 7 treatments: 2 diarrhea, 4 pneumonia, 1 other disease) and 
other groups 6 treated calves each [CTRL: in total 9 treatments (4 diarrhea, 2 
pneumonia, 3 other diseases); RU: in total 10 treatments (1 diarrhea, 7 pneumonia, 2 
other diseases); QA: in total 10 treatments (1 diarrhea, 5 pneumonia, 4 other diseases)]. 
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Other diseases were omphalitis (n = 2), thromboflibitis (n = 4), polyartritis (n = 1), 
obstipation (n = 1), and conjuctivitis (n = 1).  
3.3.2 Plasma flavonoid concentrations 
Plasma concentrations of total flavonols in QA and RU increased (P < 0.05) until d 12, 
but decreased thereafter in QA (Figure 3.1). Plasma concentrations of total flavonols 
(sum of quercetin, isorhamnetin, and tamarixetin) were higher (P < 0.05) in RU than in 
CTRL (data for quercetin metabolites not shown).  
Plasma concentrations of individual catechins were below detection limit.  
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Figure 3.1. Plasma concentrations of total flavonols from d 5 to 26 after feeding of no flavonoid () 
and after oral administration of 9 mg of quercetin/kg of BW × day as quercetin aglycone () or as 
; values are LSM ± SE, n = 7 per group.  
3.3.3 Markers for antioxidative capacity and oxidative stress 
Markers for antioxidative capacity (TEAC, FRAP; Figure 3.2A-D) changed with time, 
with TEAC increasing and FRAP decreasing from d 1 to d 5 and then remaining 
relatively stable in all groups. Absolute concentrations as well as relative changes did 
not differ among groups, but FRAP showed a group × time interaction (P < 0.001) for 
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relative changes (in CTRL from d 12 to d 19; P = 0.03 and in RU from d 5 to d 12; P = 
0.08), but no relative changes in QA and CA.  
Absolute concentrations of oxidative stress markers (TBARS, F2-isoprostanes) revealed 
huge individual variations within groups and did not show group or time differences 
(Figure 3.2 E, G). However, relative changes of both oxidative stress markers showed 
overall group effects between CA and CTRL (P < 0.05; Figur 3.2 F, H).  
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C                 FRAP, Absolute plasma values                                     D              FRAP, Plasma values relative to day 1
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E                TBARS, Absolute plasma values                                            F               TBARS, Plasma values relative to day 1
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G         F2-isoprostanes, Absolute plasma values                                    H           F2-isoprostanes, Plasma values relative to day 1
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Figure 3.2. Time course of different markers for antioxidative capacity (TEAC = trolox equivalent 
antioxidative capacity, FRAP = ferric reducing ability of plasma) and oxidative stress markers 
(TBARS = thiobarbituric acid reactive substances; F2-isoprostanes); for each parameters absolute 
plasma values are depicted in graphs A, C, E, and G, whereas graphs B, D, F, and H show 
incremental or decremental values relative to values on d 1: control (), rutin (), quercetin 
aglycone (), and green tea extract (); a-bLSM with different superscripts differ; values are LSM 
± SE, n = 7 per group. 
3.3.4 Plasma concentrations of metabolites and hormones 
Plasma concentrations of total protein increased (P < 0.001) and plasma concentrations 
of albumin decreased (P < 0.001) from d 1 to d 5 in all groups (Table 3.1). After d 5, 
there was a slight decrease (P < 0.05) for total protein and a slight increase for albumin 
(P < 0.05) until the end of the study. Plasma concentrations of urea decreased (P < 0.01) 
until d 12 in all groups and then remained relatively low (Table 3.1). Plasma glucose 
concentrations slightly increased (P = 0.01) in most groups from d 1 to d 5 and then 
variably changed up to d 26 (Table 3.1). Plasma lactate concentrations sharply 
decreased after birth up to d 5 but then remained stable up to d 26 (Table 3.1). Plasma 
NEFA concentrations decreased up to d 5 of life and partly increased again until d 12 
(Table 3.1). Plasma insulin and cortisol concentrations decreased after birth in most 
groups (P < 0.001) and then remained low (Table 3.1). All plasma concentrations 
measured were comparable among groups except for plasma cortisol, where the 
decrease after birth differed among groups reflected by group × time interaction (P < 
0.001).  
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3.4 Discussion 
At birth BW was not different among groups, as planned, and postnatal growth 
performance was not affected by treatment. The lack of differences in feed intake and 
ADG during flavonoid administration is in line with findings of Oliveira et al. (2010) 
after feeding a flavonoid-rich pomegranate extract to calves for the first 30 d of life. 
Because concentrate intake did not differ among groups, rumen development during 
first month of life was unlikely changed by flavonoid administration, as supported by 
low plasma concentrations of β-hydroxybutyrate that did not increase in flavonoid-
treated calves during the experimental period (Maciej and Hammon, unpublished 
observations). Nevertheless, plant extracts have the potential to affect rumen 
development, but may be only effective in older calves (Greathead, 2003). 
The impact of flavonoids on health status is discussed controversially. Nielsen (2008) 
found fewer diarrhea in weaned piglets after feeding natural feed additives containing a 
high amount of flavonoids. In contrast, Oliveira et al. (2010) reported no effects on 
health parameters, like incidence of diarrhea, by feeding a polyphenol-rich feed to 
newborn calves. Interestingly, we found an improved fecal score in CA compared to 
CTRL calves. In recent studies GTE were shown to inhibit diarrhea in newborn calves 
(Ishihara et al., 2001). In addition, the number of treatments was markedly reduced in 
the study of Ishihara et al. (2001), confirming our results of numerically less treated 
calves because of diarrhea in CA.  
Plasma antioxidant capacity of calves, based on TEAC and FRAP measurements, was 
not influenced by flavonoid feeding in this study. However, the sharp changes of both 
markers from d 1 to d 5 again highlights the role of colostrum feeding (Blum and 
Hammon, 2000; Hammon et al., 2013). Measurement of TEAC is dependent on the 
vitamin E analogue trolox. Because vitamin E is provided by colostrum feeding (Blum 
et al., 1997; Lindmark-Månsson and Åkesson, 2000; Zanker et al., 2000), and plasma 
TEAC also increased rapidly after first colostrum intake in calves. Our findings on 
FRAP agree with those of Gaál et al. (2006) that also showed a decline of this parameter 
after first colostrum intake. Urea is a major factor influencing FRAP (Benzie and Strain, 
1996), and albumin and urea are factors influencing TEAC (Miller et al., 1993), but 
these metabolites only changed in time and were similar among groups. Although 
plasma metabolites were not affected by treatment, decremental changes of FRAP 
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values from d 12 to d 19 in CTRL, and from d 5 to d 12 in RU, reflect changes of 
antioxidative capacity with time. 
Oxidative stress markers (TBARS and F2-Isoprostanes) did not follow a clear time-
dependent trend as seen for TEAC and FRAP. Nevertheless, TBARS increased in time 
in CTRL and decreased in CA, suggesting less oxidative stress in calves fed GTE. On 
the other hand, F2-isoprostane concentrations in plasma decreased only in CTRL, 
indicating more oxidative stress. In previous studies on calves, plasma concentrations of 
oxidative stress markers distinctly increased when calves were sick or stressed (Erisir et 
al., 2013; Ahmed and Hassan, 2007; Al-Qudah, 2009). This suggests that flavonoid 
feeding to healthy calves, as in the present study, may not change oxidative stress 
markers. A polyphenol-rich diet in humans (Nieman et al., 2013), lactating cows 
(Gohlke et al., 2013), pigs (Lühring et al., 2011) or rats (Igarashi and Ohmuma, 1995) 
also led only to slight or no changes of markers of antioxidant activity or oxidative 
stress.  
In general, methods for determination of TBARS and F2-isoprostanes were discussed to 
be inappropriate because of too low specificity and concomitantly too high inter-assay 
variation (Rimbach et al., 1999; Halliwell and Whiteman, 2004; Celi, 2011). 
Furthermore, antioxidative status tremendously differs between individuals and depends 
on medical treatment (Farombi, 2001) and season (Bernabucci et al., 2002). In addition, 
plasma flavonol concentrations were relatively low since blood sampling occurred in 
the pre-prandial stage and postprandial plasma flavonol concentration in calves 
decreased rapidly with age (Maciej et al., 2015). Therefore, variable results concerning 
antioxidative status or oxidative stress markers can be expected. Also, the amount of 
flavonoid used in this study was based on previous studies in pigs and dogs (Lesser et 
al., 2004; Reinboth et al., 2010; Lühring et al., 2011), which may not be adequate for 
colostrum- and milk-fed calves. The determination of other parameters, such as of 
protein damage, determination of vitamins E and C or of enzymatic antioxidants might 
be more appropriate.  
We assumed that quercetin feeding may affect metabolic status in calves as some 
authors postulate effects of flavonoids on glucose metabolism (Cermak et al., 2004; 
Shetty et al., 2004; Gohlke et al, 2013). However, we found no effects on pre-prandial 
plasma glucose concentrations by flavonoid feeding in this study. The increase of 
plasma glucose concentrations after birth reflects lactose intake by colostrum and milk 
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feeding as well as an increasing endogenous glucose production with age (Hammon et 
al., 2013). Because plasma glucose is highly regulated with the goal to maintain 
euglycemia, concentrations were relatively stable throughout the study and 
corresponded to earlier presented data measured in young milk-fed calves (Hadorn et 
al., 1997; Rauprich et al., 2000; Nussbaum et al., 2002). Plasma concentrations of other 
metabolites and insulin were also not affected by flavonoid feeding and simply reflected 
physiological changes during first month of life (Nussbaum et al., 2002; Schiessler et 
al., 2002; Hammon et al., 2012). Differences in plasma cortisol concentrations among 
groups on d 1 were independent of flavonoid administration as blood was sampled 
before flavonoid supplementation.  
In conclusion, effects of flavonoid treatment were much less than hoped or expected. 
However, reduced medical treatment, fewer incidences of diarrhea, and a slight effect 
on oxidative stress markers may indicate a potential health-promoting effect of 
catechins in this study. Nevertheless, evidence for biological effects of flavonoid-
containing supplements is not available for young calves. Feeding higher doses of 
flavonoids than in this study may possibly cause more distinct changes of the metabolic 
or antioxidative status in neonatal calves. In addition, use of more specific markers of 
anti-oxidative capacity or stress may be helpful in future studies. 
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General Discussion 
Rearing neonatal calves healthy and economically is still a major challenge in todayʼs 
dairy farming. Feed supplements are often claimed to provide an effective and easy way 
to improve performance of animals, but the actual use of such supplements marketed is 
manifold. Since flavonoids are ingredients in all higher plants with numerous health-
promoting properties like acting antioxidative, antiviral, or anti-inflammatory, and 
beneficial effects on metabolic key enzymes and even antidiarrheal remedies (Chapter 
1; Gálvez et al., 1995; Rao et al., 1997; Middleton et al., 2000), their use in dairy 
nutrition is comprehensible. However, biological effects in vivo require systemic BV. 
Bioavailability in particular means the absorption, distribution, metabolism, and at least 
the excretion from the organism. For calves, systemic BV is widely unknown so far. 
Therefore, this study was performed to examine BV and the biological effects of the 
most abundant flavonoids quercetin and catechin in neonatal calves.  
In the first study of this thesis (Chapter 2) the systemically availability of quercetin, 
either applied as quercetin aglycone or applied as quercetin glucorhamnoside rutin 
linked to the sugar rutinose was evaluated in newborn calves on d 2 and on d 29 of life 
to investigate two different ontogenetic states. In the second study (Chapter 3) possible 
influences of quercetin as aglycone or as rutin, and furthermore of catechin on the 
metabolic and antioxidative status in calves were examined during a 3-wk feeding from 
d 5 to 26 of life.  
In both studies of this thesis, quercetin aglycone and rutin were supplemented at an 
amount of 30 µmol/kg of BW per d. This dosage based results from companion studies 
in dairy cows (Berger et al., 2012; Gohlke et al., 2013). Both quercetin sources were fed 
as pure substances, suspended in 10 mL of water to enable oral apply of flavonoids 
during milk feeding. Therefore, possible effects can be deduced exclusively from 
flavonoid feeding what would not be the case when feeding plant extracts with mixed 
compositions or other natural products like propolis, as seen in a number of other 
studies in calves (Yaghoubi et al., 2008; Oliveira et al., 2010). In contrast to quercetin 
feeding catechin could not be fed as pure substance, but was fed by a GTE on a level of 
10 mg/kg of BW per d of original substance, containing 70.3 % catechins. Dosage of 
catechins was aligned to quercetin dosage and is shown in Table 1 of the appendix of 
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this thesis. However, plasma catechin concentrations were below the detection limit 
(data not shown), thus in further studies higher dosages should be applied.  
Studies on BV of flavonoids are conducted for a wide variety of species including 
humans (Erlund et al., 2000; Egert et al., 2008), pigs (Ader et al., 2000; Lesser et al., 
2004; Cermak et al., 2003), rats (Manach et al., 1997, 1999), dogs (Reinboth et al., 
2010), horses (Wein and Wolffram, 2013), and cows (Berger et al., 2012; Gohlke et al., 
2013). The enormous differences among the species and ages impeded a transfer of 
findings to neonatal calves (Chapter 1, section 2.2.5). Hence, this thesis shall be a basis 
for further more specific investigations on flavonoid feeding in calves. Next to 
differences among species as mentioned above, great inter-individual differences among 
calves were found in these experiments, confirming previous studies for plasma 
flavonol concentrations attributed to individual enzyme expression or differences in 
intestinal bacterial colonization (Németh et al. 2003; Manach et al., 2005). Calves for 
these studies originated from two distinct neighboring farms, thus genetic background, 
feeding of dams, and further external influences may partly account for differences 
found. Such impacts could be avoided by selecting calves from just one dairy operation 
with a common pedigree.  
In the first study of this thesis (Chapter 2), quercetin was systemically available 
reflected by increased concentrations of total flavonols, quercetin, and the quercetin 
metabolites tamarixetin, isorhamnetin, and kaempferol in blood plasma of neonatal 
calves, both after administration of quercetin as aglycone and as glucorhamnoside rutin. 
Neonatal calves are regarded as functional monogastrics until development of the 
reticulorumen allows rumination (Drackley, 2008). Therefore, BV in neonatal calves is 
more comparable to monogastric, but not to ruminant species as quercetin aglycone was 
better absorbed than rutin. This is in line with a decreasing BV of quercetin with 
ontogenesis as on d 29 a higher microbial fermentation thus lower BV due to partial 
ruminal degradation of quercetin was expected (Heinrichs and Jones, 2003; Guilloteau 
et al., 2009; Berger et al., 2012).  
However, absorption of quercetin occurred slowly, reflected in delayed and lower 
maximal reached plasma concentrations than found in monogastrics (Lesser et al., 2004; 
Reinboth et al., 2010; Chapter 2) or in adult cattle (Berger et al., 2012; Gohlke et al., 
2013; Chapter 2), although applying comparable amounts of quercetin. This once more 
underpins that results from studies on BV of other species or adult cattle cannot be 
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deduced to young calves. Furthermore, a delayed absorption of quercetin as 
glucorhamnoside rutin, but not as its aglycone was seen as result of different absorption 
sites in monogastrics (Hollman et al., 1997; Manach et al., 1997; Chapter 1). On the 
contrary, in neonatal calves quercetin aglycone and rutin administration showed the 
same slow increase in plasma concentrations, indicating similar absorption sites as well 
as a special feature in milk-fed calves because of abomasal milk clotting (Chapter 2). To 
exclude interactions with milk fed, flavonoids may be administered with water only 
instead of milk, which should result in a faster increase of plasma flavonol 
concentrations. Anyway, to determine the exact place of absorption and metabolism of 
flavonoids in calves, further studies are required like intraruminal or intraduodenal 
application of flavonoids or in vitro absorption tests of flavonoids with different bovine 
gastrointestinal tissues.  
Aside from this, the slow absorption of flavonols during BV studies (Chapter 2) seems 
to be associated with the accumulation of quercetin in plasma during long-term 
administration (Chapter 3). When elimination half-lives of flavonoids are long, repeated 
absorption of flavonoids can cause accumulation in blood plasma (Aherne and OʼBrien, 
2002; Chapter 1). Again, calves showed differences to other monogastrics like pigs, 
where long-term quercetin feeding did not lead to an accumulation in plasma, mainly 
due to much faster absorption of quercetin (Bieger et al., 2008). In calves, accumulation 
of flavonols in plasma during long-term administration was especially seen for rutin 
(Chapter 3) what is in line with findings from BV studies of a delayed peak in plasma 
flavonol concentrations after rutin feeding, especially on d 2 (Chapter 2).  
Interestingly, even without dietary flavonoid supplementation calves showed 
measurable plasma flavonol concentrations during BV studies (Chapter 2) and during 
long-term administration (data not shown; Chapter 3). This was particularly seen on day 
2 when colostrum was fed (Chapter 2) indicating once more the outstanding role of 
colostrum for health and welfare of calves (Hammon et al., 2013). In addition, to further 
clarify the source of flavonols, analysis of the respective composition of colostrum or 
calf feed is required. In the superordinate context of these studies, bovine milk or 
colostrum are probable flavonoid sources in human nutrition as well as veal rich in 
flavonoids as so called functional food. Precondition for this would be further studies 
examining the distribution of flavonoids in calves and distinct tissue analyses after 
flavonoid absorption (Chapter 1).  
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However, concentrations of metabolites and hormones measured postprandial during 
BV studies (Chapter 2) or basal during long-term flavonoid treatment (Chapter 3) were 
in line with previous studies on calves without dietary flavonoid supplementation, 
indicating physiological conditions and an unaffected metabolic status of calves by 
flavonoid feeding. Results of basal blood samples during long-term flavonoid 
administration (Chapter 3) confirmed the findings of unaffected metabolic parameters 
found in BV studies (Chapter 2). Flavonoid administration at higher dosage and a more 
distinct focus on glucose metabolism during the experimental design putatively may 
reveal effects as found in companion studies on calves (Gruse et al., 2014) or in 
monogastric animals showing an inhibited glucose uptake in intestinal cells after 
quercetin feeding (Cermak et al., 2004). Nevertheless, all data indicated the use of 
flavonoids in sensitive neonatal calves is harmless. This is noteworthy as secondary 
plant metabolites in the past mainly counted as anti-nutritive factors (Durmic and 
Blache, 2012).  
Markers of oxidative stress and of the antioxidative capacity in calves during long-term 
administration of quercetin and catechin were barely influenced by feeding regime, but 
influenced by time, reflected by physiological changes during maturation (Chapter 3). 
Colostrum as source for antioxidants like vitamins and enzymes (Lindmark-Månsson 
and Åkesson, 2000) was assumed to induce at least most of the time effects of the 
antioxidative status in this study. The distinct increase of TE (unit for TEAC) and the 
decrease of ASCE (as unit for FRAP) from shortly after birth to d 5 of life demonstrated 
the important role of feed intake. This was the first study proofing this outstanding 
influence of feed intake. However, similar changes in plasma concentrations were not 
seen for TBARS or F2-isoprostanes as oxidative stress markers. Therefore, relative 
changes from d 1 to other d were evaluated, which pointed out a possible role of 
catechin feeding. Taken together, reduced medical treatment, better fecal scores and a 
slight impact on oxidative stress markers possibly indicate health-promoting effects of 
catechins in calves. This is especially interesting und should be further examined in 
regard to the low plasma catechin concentrations found.  
Nevertheless, in this study changes in oxidative stress markers by flavonoid feeding 
were weak (Chapter 3) when compared to other studies showing more distinct 
differences in oxidative stress markers mainly in obviously impaired calves (Wernicki 
et al., 2006; Ahmed and Hassan, 2007; Al-Qudah, 2009). This was not true in the 
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studies of this thesis, where all calves were kept under similar conditions. Furthermore, 
in contrast to plasma metabolites like glucose or protein there is a lack of basic 
information, like data for physiological ranges, concerning markers for antioxidative 
capacity and oxidative stress. Anyway, this may be explained by the huge variation 
found in the distinct studies and the different methods of analysis (Chapter 1, 3), raising 
the question whether there are more appropriate markers to determine the antioxidative 
status of calves or if additional parameters should be used. As presented previously 
(Chapter 1; section 2.3.3) conceivable suggestions are the determination of vitamins E 
and C, carotenoids, bilirubin or glutathione as well as enzymatic antioxidants like 
superoxide-dismutase, catalase or glutathione-peroxidase. Moreover, a more closely 
setting of sample collection over longer time periods would allow a deeper insight in 
kinetics of flavonoid action. Additionally, in these studies only 7 calves per group were 
investigated. Using more animals per group would let findings become more 
conclusive.  
On the other hand, dietary flavonoid supplementation, namely catechin feeding, seemed 
to improve health status reflected in fewer sick calves and less diarrhea, although 
plasma catechin concentrations were below the detection limit (Chapter 3). However, 
biological effects not only depended on absolute plasma concentrations, but also on 
concentrations in target tissues, which is needed to be examined in further studies. A 
possible approach is comparing directly the effects of flavonoid supplementation from d 
of birth to a control group without flavonoid supplementation or treating sick calves 
with flavonoids compared to sick calves without flavonoid treatment with both 
approaches using an adequate number of animals. Furthermore, the chemical form or 
the galenical form in general, in which the flavonoid is applied, greatly influences BV 
and thus the biological effects (Chapter 1) as may be seen in studies that compare 
quercetin aglycone or rutin administration to natural plant extracts containing quercetin.  
In previous studies on V, urine and feces collection were the appropriate methods used 
as due to urine and feces analyses, the excretion of the investigated substance can be 
verified. Since this thesis focused on the more fundamental question if flavonoids were 
absorbed at all, no excrement was analyzed.  
In conclusion, these studies clearly showed for the first time, that quercetin is 
systemically available in newborn calves. This is a requirement for biological effects in 
the organism which already are claimed by feed producers in practical dairy nutrition. 
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The great influence of maturation and ontogenetic stage of young calves on BV of 
flavonoids was demonstrated just as the influence of the chemical form of the 
administered flavonoids. It was evaluated to what extend flavonoids affect the 
metabolic and antioxidative status in neonatal calves, shown in slight changes of the 
respective markers. This all contributes to a better understanding of the usage, the mode 
of action, and the benefit of flavonoids as ʽnaturalʼ health-promoting feed supplements.  
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Summary 
Flavonoids are secondary plant metabolites with numerous health-promoting properties. 
The feeding industry widely use flavonoids as ʽgreenʼ feed supplements even scientific 
evidence of their value are often hypothetical. Due to their high susceptibility to 
diseases, the use of flavonoids in neonatal calves might be especially useful. However, 
to determine biological effects in vivo, flavonoids must be systemically available in 
calves, but this is not known yet. Therefore, the aim of this study was to determine BV 
and their biological effects of the most abundant flavonoids quercetin and catechin in 
neonatal calves.  
In part one of the study, calves (n = 7 per group) were fed quercetin as aglycone or as 
glucorhamnoside rutin or no flavonoid (control group) on d 2 and 29 of life. Blood 
samples were taken in defined time intervals before and until 48 h after flavonoid 
administration via jugular vein catheters. Quercetin and its methylated (isorhamnetin, 
tamarixetin) and dehydroxylated (kaempferol) metabolites were analyzed in blood 
plasma using HPLC with subsequent fluorescence detection. It was shown that 
quercetin is systemically available both as aglycone and as rutin in neonatal calves, but 
BV of quercetin aglycone was higher than BV of rutin as previously shown in 
monogastric species. Furthermore, BV of quercetin and its metabolites was greater on d 
2 than on d 29 of life and the proportion of quercetin metabolites differed greatly 
between the two d, which possibly can deduced to maturation of the gastrointestinal 
tract.  
In part two of the study effects of a three-wk administration of quercetin aglycone, rutin 
or a green tea extract containing mainly catechins, on performance, health, and the 
antioxidative capacity and oxidative stress in neonatal calves were evaluated. A fourth 
group was used as control group (n = 7 calves per group) and did not receive any 
flavonoid sopplementation. No group differences were found for zootechnical 
parameters, but a slight benefit in health status when catechins were fed. Effects of 
flavonoid feeding on metabolic status were not seen in this study, but total protein, 
albumin, urea, lactate, glucose, NEFA, insulin, and cortisol reflected typical time 
changes during postnatal calf development. Markers of the antioxidative capacity in 
blood plasma (TEAC, FRAP) showed incisive differences in time, seen in a sharp 
increase of TEAC and in a decrease of FRAP plasma concentrations postpartum. 
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However, oxidative stress markers (TBARS, F2-isoprostanes) did not illustrate distinct 
group and time effects due to great interindividual variances.  
Taken together, this study clearly demonstrated that the bioavailability of quercetin is 
determined by its chemical form and depends to a major extent on physiological 
processes of digestion and gastrointestinal maturation in calves. In contrast, the 
influence of flavonoids on the antioxidative status did not show clear results, thus an 
improvement of the antioxidative status in neonatal calves by flavonoid administration 
cannot be confirmed by this study.  
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Zusammenfassung 
Flavonoide sind sekundäre Pflanzeninhaltsstoffe, denen zahlreiche gesundheits-
fördernde Eigenschaften zugesprochen werden. In der Futtermittelindustrie haben 
Flavonoide deshalb als „grüne“ Zusatzstoffe bereits weitreichend Einzug erhalten, auch 
wenn wissenschaftlich fundierte Nachweise bezüglich ihrer Wirkung im Nutztier 
oftmals hypothetisch sind. Besonders für neugeborene Kälber scheint aufgrund ihrer 
erhöhten Krankheitsanfälligkeit der Einsatz von pflanzlichen Zusatzstoffen sinnvoll. 
Allerdings müssten Flavonoide für biologische Effekte systemisch im Kalb verfügbar 
sein, wofür es bis jetzt noch keine Belege gibt. Somit war es Ziel dieser Arbeit die 
Bioverfügbarkeit und die biologischen Effekte der weit verbreiteten Flavonoide 
Quercetin und Catechin beim neugeborenen Kalb zu untersuchen.  
Dazu erfolgte im ersten Teil dieser Studie die Fütterung von Quercetin als reines 
Aglykon oder mit entsprechendem Zuckerrest als Glukorhamnosid Rutin am 2. und 29. 
Lebenstag der Kälber (n = 7 pro Gruppe). Vor, sowie bis zu 48 Stunden nach der 
Flavonoidapplikation, wurden in definierten Zeitabständen Blutproben gewonnen und 
der Gehalt an Quercetin sowie der jeweiligen methylierten (Isorhamnetin, Tamarixetin) 
und dehydroxylierten (Kaempferol) Metaboliten mittels Hochleistungsflüssigkeits-
chromatographie mit anschließender Fluoreszenzdetektion analysiert. Es konnte gezeigt 
werden, dass Quercetin sowohl als Aglykon als auch als Rutin systemisch im Kalb 
verfügbar war, wobei die systemische Verfügbarkeit von Quercetin nach Fütterung des 
Aglycons höher war als nach Fütterung von Rutin. Weiterhin wurde am 2. Lebenstag 
eine deutlich höhere Bioverfügbarkeit von Quercetin und seinen Metaboliten festgestellt 
als am 29. Lebenstag. Auch war der Anteil der einzelnen Quercetinmetabolite an der 
Gesamtflavanolkonzentration im Blutplasma stark verändert, was möglicherweise auf 
den unterschiedlichen Grad der Darmentwicklung am 2. und 29. Lebenstag 
zurückgeführt werden kann. 
Im zweiten Teil der Studie wurde die Leistungsentwicklung, der Gesundheitsstatus 
sowie die antioxidative Kapazität und der oxidative Stress bei Kälbern untersucht, 
denen über einen Zeitraum von drei Wochen entweder Quercetin in Form des Aglycons 
oder als Rutin oder ein Grünteeextrakt, der hauptsächlich Catechine enthielt, verabreicht 
wurde. Eine vierte Kälbergruppe bekam keine Flavonoide zugefüttert und diente als 
Kontrollgruppe (n = 7 pro Gruppe). Hierbei konnten in den erhobenen zootechnischen 
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Parametern keine Gruppenunterschiede, jedoch ein leichter Vorteil durch die Fütterung 
von Catechin im Gesundheitsstatus, festgestellt werden. Effekte der Flavonoidfütterung 
auf den Stoffwechsel der Kälber, ausgedrückt durch Gesamtprotein, Albumin, 
Harnstoff, Laktat, Glukose, nicht-veresterte Fettsäuren, Insulin und Cortisol, konnten in 
dieser Studie nicht dargelegt werden, jedoch wiesen diese Parameter 
entwicklungsphysiologische Zeitveränderungen auf. Marker der antioxidativen 
Kapazität im Blutplasma (TEAC, FRAP) zeigten prägnante Zeitunterschiede, 
ausgedrückt durch einen deutlichen Anstieg der TEAC und einen ausgeprägten Abfall 
der FRAP nach der Geburt. Marker für den oxidativen Stress (TBARS, F2-Isoprostane) 
hingegen zeigten im Blutplasma aufgrund der starken individuellen Streuung keine 
eindeutigen Behandlungs- und Zeiteffekte.  
Zusammenfassend konnte mit dieser Studie gezeigt werden, dass die Bioverfügbarkeit 
von Quercetin durch dessen chemische Form determiniert ist und zum größtenteils von 
verdauungsphysiologischen Vorgängen und der Darmreifung des Kalbes abhängig ist. 
Dagegen zeigten die hier durchgeführten Untersuchungen zum Einfluss der Flavonoide 
auf den antioxidativen Status der Kälber keine eindeutigen Ergebnisse, so dass eine 
Verbesserung des antioxidativen Status nach Flavonoidgabe bei neugeborenen Kälbern 
mit dieser Studie nicht bestätigt werden konnte.  
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Table 1 Appendix. Calculation of flavonoid dosage 
Item Formula 
Molar mass, 
g/mol 
Flavonoid dosage 
mg/kg 
BW 
µmol/kg 
BW 
Rutintrihydrate (group RU) C27H30O16 * 3 H2O 664.6 20 30 
Quercetindihydrate (group QA) C15H10O7 * 2 H2O 338.3 10 30 
     
Water H2O 18.0   
Rutinose C12H22O16 326.3   
Rutin, minus water  610.5   
Rutin, QE
1
, minus water and 
rutinose 
 
284.2/ 
302.2
2
 
9 30 
Quercetin, QE, minus water   302.2 9 30 
Polyphenon 60 (group CA)   10  
Catechin content 70.3 %   7  
Epigallocatechin  C15H14O7 306.267 1.90 6.20 
Epicatechin  C15H14O6 290.260 0.64 2.20 
Epigallocatechin gallate  C22H18O11 458.370 2.88 6.28 
Epicatechin gallate  C22H18O10 442.370 0.70 1.58 
Gallocatechin gallate  C22H18O11 458.370 0.21 0.46 
Catechin gallate  C22H18O10 442.370 0.03 0.07 
Gallocatechin  C15H14O7 306.267 0.52 1.70 
Catechin  C15H14O6 290.260 0.14 0.48 
Sum, CA   7 19 
1 
QE = Quercetin equivalents.
 
2
 Only theoretically due to binding of 2 H and 1 O from crystalline water. 
 
 
 
APPENDIX 
 
    
 
A                  Day 2                                                               B                                           Day 29
Time relative to feeding, h
0 2 4 6 8 10 12 24 48
Q
u
er
ce
ti
n
, 
n
m
o
l/
L
0
50
100
150
200
Time relative to feeding, h
0 2 4 6 8 10 12 24 48
Q
u
er
ce
ti
n
, 
n
m
o
l/
L
0
50
100
150
200
 
 
C                  Day 2                                                               D                                           Day 29
Time relative to feeding, h
0 2 4 6 8 10 12 24 48
Is
o
rh
a
m
n
et
in
, 
n
m
o
l/
L
0
20
40
60
80
100
Time relative to feeding, h
0 2 4 6 8 10 12 24 48
Is
o
rh
a
m
n
et
in
, 
n
m
o
l/
L
0
20
40
60
80
100
 
 
E                  Day 2                                                               F                                           Day 29
Time relative to feeding, h
0 2 4 6 8 10 12 24 48
T
a
m
a
ri
x
et
in
, 
n
m
o
l/
L
0
25
50
75
100
125
150
Time relative to feeding, h
0 2 4 6 8 10 12 24 48
T
a
m
a
ri
x
et
in
, 
n
m
o
l/
L
0
25
50
75
100
125
150
 
 
APPENDIX 
 
    
G                  Day 2                                                               H                                           Day 29
Time relative to feeding, h
0 2 4 6 8 10 12 24 48
K
a
em
p
fe
ro
l,
 n
m
o
l/
L
0
2
4
6
8
10
12
Time relative to feeding, h
0 2 4 6 8 10 12 24 48
K
a
em
p
fe
ro
l,
 n
m
o
l/
L
0
2
4
6
8
10
12
 
 
Figure 1 Appendix. Plasma concentration-time curves of quercetin (A, B), isorhamnetin (C, D), 
tamarixetin (E, F), and kaempferol (G, H) after oral administration of 9 mg of quercetin/kg of BW 
× d as quercetin aglycone (), rutin trihydrate (), or no flavonoid (●) on d 2 and 29 of life. Values 
are LSM ± SE, n = 7 per group (Chapter 2).  
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Figure 2 Appendix. Plasma concentrations of total protein (A, B), albumin (C, D), lactate (E, F), 
and urea (G, H) after oral administration of 9 mg of quercetin/kg of BW × d as quercetin aglycone 
(), rutin trihydrate (), or no flavonoid (●) on d 2 and 29 of life. Values are LSM ± SE, n = 7 per 
group (Chapter 2).  
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Figure 3 Appendix. Plasma concentrations of total protein (A), albumin (B), lactate (C), glucose 
(D), NEFA (E), urea (F), insulin (G), and cortisol (H) after oral administration of quercetin 
aglycone (), rutin trihydrate (), a green tea extract (○) or no flavonoid (●). Values are LSM ± 
SE, n = 7 per group (Chapter 3).  
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